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1. Background 
Bone tissue is one of the most frequently used tissues for transplantation. 
Annually more than one million patients are treated worldwide for skeletal 
complications in the field of orthopedic surgery, plastic surgery, maxillofacial 
surgery, and neurosurgery. The use of autologous bone grafts is still considered 
to be the golden standard, but there are several major disadvantages 
associated with this technique, for example: low availability of the 
transplantable tissue, postoperative morbidity and lack of functional shape of 
the transplant. Therefore, the development of alternatives to autologous 
bone is a very relevant issue in bone reconstructive surgery. The aim of this 
chapter is to provide an overview of bone biology, bone tissue engineering, 
and the fundamentals of the chosen route to establish injectable bone fillers 
for bone tissue engineering applications. The latter is the main topic of the 
research described in this thesis. 
 
2. Bone 
Bone is a unique tissue that gives mechanical support to the body. It is a 
major reservoir of calcium minerals (hydroxyapatite) and bone marrow, from 
which blood cells originate. Bone tissue is composed of collagen, water, cells, 
and blood vessels. Cells present in bone are the supporting cells, which are 
called osteoblasts and osteocytes, and remodelling cells, which are called 
osteoclasts.  
Osteoblasts are the skeletal cells responsible for the synthesis and deposition 
of bone mineral, and hence the mineralization of the bone extracellular 
matrix. During their differentiation, osteoblasts become isolated in a cavity of 
bony matrix as a result of mineral deposition. At the end of the differentiation 
process, these isolated cells are called osteocytes. Osteocytes have 
numerous long cell extensions (canaliculi) rich in microfilaments that are 
organized during the formation of the matrix and before its calcification. 
Through these canaliculi, osteocytes exchange nutrients and waste products. 
Osteoclasts are constantly eroding deposited bone, while osteoblasts are 
constantly replacing osteoid and minerals. In this way, bone is a dynamic 
tissue that is being formed and broken down in a continuous cycle in 
response to physical and hormonal factors.1 
Two types of bone tissue are observed in the mature human skeleton: cortical 
(dense) and trabecular (cancellous) bone. Although macro- and 
microscopically different, the two forms are identical in their chemical 
composition. Cortical bone, which comprises 80% of the skeleton, is dense 
and compact, has a slow turn-over rate, a high resistance to bending and 
torsion, and is localized in the outer part of all skeletal structures. The major 
part of the cortical bone is calcified and its function is to provide mechanical 
strength and protection. Trabecular bone represents 20% of the skeletal mass, 
and 80% of trabecular bone is found inside the long bones throughout the 
skeleton of the vertebrae, and in the inner portions of the pelvis and other 
large flat bones. Trabecular bone is less dense, more elastic, and has a higher 
turn-over rate than cortical bone (Figure 1).2  
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Figure 1: Structure of bone. 
Depicted is a part of a femur, which 
contains both trabecular as well as 
cortical bone. (modified picture, 
web-books.com) 
 
 
 
 
 
 
 
Bone is also one of the few tissues capable of self-regeneration. For instance, 
a bone fracture activates osteogenesis and, eventually, the fracture heals 
without any scar formation. Unfortunately, this ability for self-regeneration has 
limitations: if the size of large bone defects exceeds a certain threshold, the 
capacity of the body to repair these defects is insufficient. These defects, 
which are known as critical-sized defects, do not heal spontaneously without 
using bone replacing materials to restore the defect.  
 
3. Tissue Engineering 
Tissue engineering attempts to develop functional substitutes for damaged 
tissues and is defined as ‘an approach in generating renewable source of 
transplantable tissues by using the principles of engineering, physical 
sciences, and medicine.3 Tissue engineering strategies can be used to create 
several different types of tissues, including tendon, muscle, nerve, cartilage 
and bone. Tissue engineering strategies are based on three key elements 
(Figure 2): 
1) a scaffold or carrier material 
2) biological compounds (e.g. growth factors, antibiotics, etc.) 
3) cells 
 
 
Figure 2: Tissue engineering 
principle. Various strategies can be 
chosen to create/restore tissue by 
selecting one, a combination of 
two, or all three key elements. For 
example, the usage of a scaffold 
material combined with growth 
factors and/or cells. 
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The scaffold provides mechanical support and serves as a substrate to which 
cells attach, and subsequently proliferate and undergo differentiation. 
Furthermore, the scaffold can serve as a delivery vehicle for biological 
compounds that have the capacity to influence local cell behaviour (e.g. 
growth factors) or inflammation (e.g. antibiotics). 
In view of bone tissue engineering constructs, these can be subdivided into 
osteoconductive, osteogenic, and osteoconductive constructs.4 
Osteoconductive bone tissue engineering constructs support bone formation 
by serving as a guide for bone formation, which facilitates bone growth along 
the construct surface and hence the bridging of the gap between two bone 
ends. For osteogenic bone substitutes, cells of the osteoblastic lineage (e.g. 
osteoprogenitor or osteoblast-like cells) are added to a porous scaffold to 
stimulate the formation of bone tissue from within the construct. For 
osteoinductive bone substitutes, osteoinductive growth factors (e.g. 
transforming growth factor-β1) are combined with the scaffold to induce 
desired biological responses (e.g. cell differentiation or migration). 
Additionally, a combination of osteogenic and osteoinductive bone tissue 
engineering constructs is possible. 
 
3.1 Scaffolds 
Calcium phosphate ceramics 
Calcium phosphate (CaP) ceramics are particularly promising as materials in 
bone tissue engineering owing to their similarity to biological apatites, the 
mineral component of bone. In addition to being non-toxic, CaP ceramics 
are biocompatible and not recognized as foreign in the body. Although CaP 
ceramics are popular implant materials for clinical applications, their 
resorbability is low. Therefore, methods have been developed to enhance 
tissue ingrowth and degradation rate by introducing porosity in the CaP 
ceramics. The creation of porosity, however, is inevitably associated with a 
loss in mechanical properties.  
Nowadays, various CaP ceramics are available for biomedical use (Table 1), 
which differ in chemical composition (Ca/P ratio, crystalline phase) and 
stability. 
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Table 1: Commercialy available ceramics and cements. (Habraken et.al.5) 
 
 
These CaP ceramic materials include hydroxyapatite (HA), beta-tricalcium 
phosphate (β-TCP), biphasic calcium phosphate (BCP), amorphous calcium 
phosphate (ACP), carbonated apatite (CA), and calcium deficient 
hydroxyapatite (CDHA). Of these, the two mostly used materials for 
biomedical applications will be described in more detail below. 
HA (chemical denotation: Ca10(PO4)6(OH)2) is the most stable form of CaP 
under physiological pH at body temperature. HA has a Ca/P ratio of 1.67, 
which is similar to bone mineral. HA is made by sintering precipitated CaP salts 
at temperatures above 1000°C. This sintered HA is hardly soluble under 
physiological conditions and its mechanical properties are superior to those of 
other CaP compositions. However, HA hardly shows any cellular resorption by 
osteoclasts, macrophages, or other giant cells, unless the particle size is small 
enough for phagocytosis.6 Therefore, HA is considered to be non-resorbable, 
in contrary to other CaP compositions that show substantial dissolution and 
resorption.  
The chemical formula of tricalcium phosphate (TCP) is Ca3(PO4)2 and it is 
similar to the amorphous component of bone.7 TCP has a Ca/P ratio of 1.5, 
and two different phases of TCP can be generated, which are known as α- 
and β-TCP. Variation in humidity and sintering temperature determine the 
phase of TCP that is formed. The β-TCP form remains if the temperature is 
below 1100°C; above this temperature, β-TCP is transformed into α-TCP.8 α-
TCP is unstable in water, in which it becomes hydrolysed to form an apatite-
like structure. The β-TCP form is less soluble and less reactive than α-TCP, and is 
commonly used in combination with HA (biphasic CaP ceramic). Due to the 
solubility of TCP, dissolution and reprecipitation occurs in vivo. These processes 
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result in a phase transformation into carbonated apatite, and resorption by 
osteoclasts, macrophages, or other giant cells.9  
 
Mechanical strength 
Mechanical properties are a considerable concern regarding the use of CaP 
ceramics. The compressive strength of cortical and trabecular bone varies 
depending on the bone density, from 130 to 180 MPa and 5 to 50 MPa, 
respectively. For tensile strength, these values fluctuate from 60 to 160 MPa 
and 3 to 15 MPa, respectively. Dense sintered CaP ceramics may reach 
compressive strengths of 300 to 900 MPa, which are substantially higher than 
those of cortical bone. Tensile strengths of dense sintered CaP ceramics 
reach values of 40 to 300 MPa, which are similar or higher than those of 
cortical bone.10 However, the lack of elasticity makes virtually all CaP 
ceramics brittle, and therefore, less suitable for clinical application under 
load-bearing conditions. It needs to be emphasized that the values presented 
above are valid for dense sintered CaP ceramics. In view of this, the 
mechanical properties of porous CaP ceramics are prone to decrease 
substantially below those of dense equivalents.9  
 
Porosity 
In bone tissue, porosity within the mineralized extracellular matrix allows 
transport of nutrients and waste in cortical bone, and space for the marrow 
cavity in trabecular bone. The pore size in cortical bone ranges from 1 to 100 
µm (volumetric porosity 5-10%), whereas trabecular bone contains pores of 
200 to 400 µm (volumetric porosity 70-90%).9 
Although porosity is devastating for the mechanical properties of CaP 
ceramics, it enhances degradation of and tissue ingrowth into CaP ceramics. 
For the mechanical performance of synthetic bone substitute materials, it is 
important to gain control over the balance between material degradation 
and tissue ingrowth as this balance parallels the total mechanical strength of 
the implant. In more detail, this means that parameters including material 
properties (biocompatibility, osteoconductivity and degradation), pore 
geometry, application site (vascularization, weight loading, defect 
dimensions), and addition of cells and/or growth factors are important for the 
total mechanical strength of an implanted bone substitute. Since each 
application requires its own specific degradation rate, no general optimized 
pore size and architecture for bone substitutes can be given.9 
Furthermore, the addition of degradable substances like mannitol, proteins 
(collagen, gelatin), carbohydrates (chitosan, alginate, starch) or other 
polymers (polylactic/polyglycolic acids) can be introduced to create porosity 
(Table 2). Two of these additives (polylactic/polyglycolic acid and gelatin) will 
be discussed in more detail later. 
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Table 2: Summary of polymers 
used in combination with CaP 
ceramics and cements. 
(Habraken et al.5) 
 
 
 
 
 
 
 
 
3.2 Growth Factors 
The importance of growth factors for tissue regeneration and repair has led to 
the development of new tissue engineering treatment strategies, which 
consist of the local delivery of growth factors at the implantation site following 
release from a synthetic carrier material. For bone tissue engineering, the 
predominant carrier materials are CaP ceramics, either or not combined with 
a polymeric additive.5,11-13 Growth factors, such as platelet derived growth 
factor (PDGF), insulin-like growth factor (IGF), bone morphogenetic protein-2 
(BMP-2), BMP-4, BMP-7/OP-1, and transforming growth factor-β1 (TGF- β1) 
have been given major emphasis in bone tissue engineering.5,13,14 These 
growth factors play an essential role in bone growth and remodelling. In 
postnatal skeletal regeneration, PDGF is important for inducing proliferation of 
undifferentiated mesenchymal cells. It is an important mediator for bone 
healing and remodelling during trauma and infection. It can enhance bone 
regeneration in conjunction with other growth factors, but is unlikely to 
provide osteogenic signals itself.14 IGF has an important role in general growth 
and maintenance of the body skeleton. The effect of local application of IGF 
alone in craniofacial skeletal defects has not yet shown a clear potential for 
enhancement of bone regeneration in the reported dosages.14 The most 
commonly investigated, and most effective growth factors in terms of 
osteogenesis and osseous defect repair are the members of the transforming 
growth factor (TGF) superfamily, which includes TGF-βs and BMPs.14,15 TGF-β is 
a 25 kDa polypeptide consisting of five subtypes: TGF-β1 to TGF-β5. While the 
first three subtypes are found in mammals, TGF-β4 is present in chicken and 
TGF-β5 in amphibians.16 TGF-β plays a significant role in wound healing by 
enhancing the repair of injured tissue, including bone tissue. TGF-β regulates 
cell proliferation, differentiation, migration, and extracellular matrix 
production.17-19 In bone defect studies, different carrier materials enriched 
with TGF-β1 have shown enhanced bone defect healing in different animal 
models at various sites.20 
Finally, BMP is the most widely used inductive factor in bone tissue engineering 
applications. BMPs mainly act as a differentiation factor on mesenchymal 
stem cells. With BMP-2 and BMP-7/OP-1, as the most important subtypes of 
BMP, which have a strong effect on inducing bone.21-25 The osteoinductive 
properties of BMPs have been widely studied in various animal models26,27 and 
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have recently been evaluated in clinical trails.28-30 Furthermore, products for 
bone regeneration have become commercially available, like bone graft 
substitutes already containing BMP-7/OP-1 (Stryker Biotech, Hopkinton, MA, 
USA) or BMP-2 (Medtronic, Minneapolis, MN, USA). 
 
3.3 Cells 
To achieve immediate presence of (committed) cells within the centre of 
tissue engineering constructs, the combination of cells and scaffold within 
one single tissue engineering construct has been explored in the recent 
decade. For bone tissue engineering, the majority of these combined 
constructs include synthetic scaffolds in combination with mesenchymal stem 
cells.31-33 These mesenchymal stem cells are commonly derived from the bone 
marrow stroma, which provides a unique cellular reservoir for the engineering 
of bone tissue. Bone marrow consists of a heterogenous population of cells 
that have the potential to differentiate into bone, cartilage, adipocytes or 
hematopoietic supporting tissues.1,34 More interestingly, bone marrow contains 
osteoprogenitor cells, which proliferate and differentiate into osteoblasts. 
Unfortunately, a key limitation in the use of bone marrow cells for bone tissue 
engineering is the relatively low number of osteoprogenitor cells in the marrow 
stroma: data in the literature demonstrated that the osteoprogenitor cell 
component is at most 0,001% of the total cellular component in a marrow 
sample.35,36 Therefore, techniques have been developed to select and 
expand the population of progenitor cells from bone marrow.36-38 In view of 
this, various studies have already shown that culturing osteoprogenitor cells in 
media supplemented with dexamethasone, ascorbic acid, and β-
glycerophosphate initiates processes that direct the osteoprogenitor cells into 
an osteoblastic differentiation pathway.39,40 As a result, these osteoblast-like 
cells produce and mineralize bone tissue (known as osteoid). Furthermore, a 
number of growth factors, including TGF-β, BMP, IGF and PDGF, are produced 
by osteoblasts, which as mentioned before play an important role in 
regulating growth and differentiation of bone. 
 
3.4 Ideal bone tissue engineering construct 
The current major drawbacks of cell-based bone engineering are the low 
yield of cells with bone inducing capacities, the lack of standardized 
expansion as well as differentiation of progenitor cells, and the non-uniformity 
of cell-based tissue engineering constructs due to the necessity to use 
autologous cells. Furthermore, the use of growth factors is expensive, and the 
correlation between growth factor bioactivity and release or retention is 
delicate. Since the growth factor needs to induce bone formation locally and 
not systemically, the released protein only has a short time to attract cells, 
before its clearance from the application site. Therefore, a off-the-shelf bone 
tissue engineered construct solely consisting of a scaffold material obtains 
faster FDA approval, and avoids the addition of cells and/or growth factors to 
the construct. 
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The ideal tissue engineered construct would be a scaffold: 
• possessing osteogenic and osteoinductive properties; 
• perfectly moldable to the required dimensions; 
• possessing sufficient mechanical properties; and 
• containing an interconnective porous network to allow cells to 
penetrate into the scaffold. 
A high potential candidate material for bone tissue engineering combining all 
of these requirements is injectable CaP cement.  
 
4. Injectable CaP cements  
 
4.1 Material properties & tissue response 
In the early eighties, Brown and Chow were the first to describe the principles 
of a self-setting CaP cement.41 CaP cements consist of a mixture of powder 
(containing one or more solid compounds of calcium and/or phosphate salts) 
and liquid (water or an aqueous solution). The formed paste hardens as a 
result of the entanglement of the newly formed crystals.42 Already, lots of 
different formulations of CaP cements have been investigated. In general, 
two types of cements are being used: apatite cements that set into HA, 
carbonated apatite (CA) or calcium-deficient hydroxyapatite (CDHA), and 
brushite cements that set into brushite as an end product. The apatite 
cements have good mechanical properties compared to brushite cements, 
while brushite cements are faster degrading than apatite cements.5 It is 
known that CaP cements can disappear due to passive and/or active 
resorption. Passive resorption is based on the solubility of the implant 
components, which is generally higher in CaP cements compared to CaP 
ceramics due to the larger crystal size of the latter. Other material properties 
involved in this type of resorption are the total material porosity, final cement 
composition (hydroxyapatite is less soluble than other CaP cements), pH in 
the implant region, and ionic substitution.43 Active resorption is due to the 
local activity of cells such as monocytes/macrophages and osteoclasts.44 
Cellular mechanisms to resorb CaP cements include both local reduction of 
the pH and phagocytosis. Already, pre-set CaP cement implants have shown 
to be an excellent osteoconductive material for bone tissue engineering 
purposes, without evoking any inflammatory responses. Nevertheless, porosity 
is needed to accelerate tissue ingrowth and degradation rate of the CaP 
cement.45-47  
 
4.2 Porosity 
For CaP cements lacking interconnected macropores (diameter > 100 μm), 
active resorption is localized only on the outer surface of the material. 
Consequently, the substitution of the implant by bone tissue is slow.48,49 
Therefore, for porous CaP cements, the passive as well as active resorption 
rate and bone ingrowth can increase significantly, as a result of an increase in 
both specific surface area and enhanced tissue ingrowth into the material 
porosity.50-52 
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CaP cements contain an intrinsic nanoporosity. However, this nanoporosity 
only allows transport of nutrients and waste through the material and the 
dimensions of this nanoporosity are insufficient to obtain tissue ingrowth.53 
Therefore, studies have been done to introduce macro- and/or microporosity 
in CaP cements to allow fast bone ingrowth and accelerate cement 
degradation. For example, del Real et al.54 used sodium bicarbonate to 
obtain CO2-gas bubbles. However, the created pores were irregularly shaped 
and the compression strength dropped to very low values compared to the 
original (dense) material. A solution to create more controllable pores is the 
incorporation of polymeric microparticles like PLGA or gelatin, which 
generates porosity after degradation.55-59 
 
Polylactic/polyglycolic acid 
Polylactic/polyglycolic acid derived polymers are composed of one or more 
of three different hydroxyl acid monomers, D-lactic, L-lactic and/or glycolic 
acids. Different formulations are known, such as polylactic acid (PLA, PLLA), 
polyglycolic acid (PGA), and poly(D,L-lactic-co-glycolic) acid (PLGA). The 
polylactic/polyglycolic acids are biocompatible, non-toxic and their 
degradation properties can modified by changing parameters, including 
molecular weight, tacticity, or the lactic to glycolic ratio in case of PLGA.60 
The degradation mechanism is based on hydrolysis in which the glycolic acid 
degrades faster than the polylactic acid. Therefore, polymeric PLGA 
microparticles were created which can be introduced in CaP cement (Figure 
3).56,58,61 
 
Figure 3: Microcomputed 
tomography image of 30/70 wt% 
PLGA/Ca-P cement composite.  In 
the μCT reconstruction, PLGA 
microparticles appear as pores in 
the Ca-P cement. (Ruhé et al.12) 
 
 
 
 
 
 
Habraken et al.57 showed that incorporating PLGA microparticles in CaP 
cement resulted in decreased mechanical properties compared to 
nanoporous CaP cement, but mechanical properties were within 
manageable ranges. Incorporated PLGA microparticles demonstrated to be 
hydrolysed within 6 to 12 weeks and as a consequence created 
microporosity.57 Generally, the degradation rate of the PLGA microparticles is 
faster than the surrounding CaP scaffold. Therefore, the inclusion of PLGA 
microparticles leads to the creation of microporosity into the CaP scaffolds. 
Additionally, the incorporation of PLGA microparticles can be used to allow 
drug and growth factor delivery.12,62   
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Gelatin 
Gelatin is a natural polymer, which is derived from collagen, and is commonly 
used for medical purposes, because of its biodegradability63-65 and 
biocompatibility66,67 in physiological environments. During the fabrication 
process of commercially available gelatin, either a positively-charged basic 
gelatin (type A), or a negatively-charged acidic gelatin (type B) at 
physiological pH can be obtained.68 Gelatin microparticles can be produced 
by a water-in-oil emulsion technique.69 Subsequently, these microparticles 
can be incorporated in CaP cement.59 Furthermore, the gelatin 
microparticles can be physically and chemically crosslinked in order to 
increase thermal and mechanical stability of the gelatin under physiological 
conditions, as well as control the rate of degradation.69,70 
The positively-charged basic gelatin (type A) and negatively-charged acidic 
gelatin (type B) allow growth factor loading of the gelatin microparticles. 
Therefore, acidic gelatin with an isoelectric point (IEP) of 5.0 can be used as a 
carrier for alkaline proteins, while alkaline gelatin with a IEP of 9.0 can be used 
for the release of acidic proteins.63,71  
 
4.3 In situ setting 
The main advantage of CaP cements over CaP ceramics are the handling 
properties. The CaP cement can be injected directly into a bone defect, is 
easy to keep in place, and can even be shaped before complete setting. 
The injectable in situ setting of the cement results in an optimal fill of the 
cement with the defect dimensions. However, the CaP cement must be 
applied before the initial setting and the wound should be closed after the 
final setting time. Otherwise, CaP cements could disintegrate upon early 
contact with aqueous solutions, or body fluids such as blood.72  
Depending on the application, CaP cements should have an initial setting 
time between 3 and 8 minutes, and a final setting time below 15 minutes. 
Further, the time between initial setting and final setting should be 
appropriate to allow the clinician to mold and apply the cement for the 
desired application. Already, successful experiments have been performed 
with injectable CaP cements, which were characterized by fast deposition of 
new bone on the cement surface.48,73-79 
 
Objectives of this thesis 
The work described in this thesis is part of the ‘new bone’ project at the 
Department of Periodontology & Biomaterials of the Radboud University 
Nijmegen Medical Center (Nijmegen, the Netherlands). The general aim of 
this project is the creation of an injectable self-setting CaP cement as an 
appropriate scaffold material for bone tissue regeneration. This bone graft 
substitute should possess a porous structure to allow tissue ingrowth, and 
should have a gradual resorption to allow replacement of the synthetic 
material by autologous, newly-formed bone tissue. Furthermore, the possibility 
to enhance the performance of CaP cements by the inclusion of polymeric 
microparticles with a time-dependent release of bone regenerating growth 
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factors is a topic of investigation. The research described in this thesis covers 
experimental work on the following subaims of the ‘new bone’ project: 
 
1. Evaluation of the in vitro cytocompatibility of CaP cement as a scaffold 
material for a cell-based tissue engineering approach. 
2. Evaluation of the in vivo biocompatibility of CaP cement incorporated 
with poly (D,L-lactic-co-glycolic acid) (PLGA) microparticles. 
3. Evaluating if in vivo bone ingrowth results in an increase of mechanical 
strength of implanted CaP/PLGA composites. 
4. Evaluation of the bone augmentation properties of an injectable 
CaP/PLGA composite either or not loaded with TGF-β1 in vivo.  
5. Evaluation of the in vivo degradation properties and subsequent bone 
formation of implanted CaP/gelatin composites. 
6. Evaluation of the in vivo bone response and mechanical strength of an 
injectable CaP/gelatin composite either or not loaded with TGF-β1.   
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Introduction 
Currently, the use of autologous and allogenous bone grafts is the method of 
choice for the treatment of large bone defects as caused by trauma, disease 
or tumor resection. However, both of these methods are associated with 
significant clinical problems, like donor site morbidity and the possible transfer 
of disease. In view of this, innovative bone engineering techniques have been 
introduced, which include the use of a suitable scaffold in combination with 
mesenchymal stem cells.1-8 Although the  achieved results hold a promise, the 
final goal, i.e. the safe and reliable healing of large bone defects, is not 
accomplished yet. Current drawbacks of cell-based bone engineering are 
the very low yield of cells with bone inducing capacities and the lack of 
standardized expansion as well as differentiation of progenitor cells. As a 
consequence, the reproducibility and predictability in human patients is low. 
Several solutions have already been suggested to solve this problem, like the 
use of cell selection 9-11,  dynamic cell culture (flow perfusion system)12-16 or 
encapsulation of cells in microspheres.17-20 The final cell population has to be 
incorporated in a scaffold material that possesses intrinsic osteophilic 
properties. For bone purposes, the ideal scaffold material is considered to be 
bioactive, slowly biodegradable, moldable and easy to apply. The scaffold 
material also needs certain porosity and the pores must have 
interconnectivity to allow tissue ingrowth and stabilization. The recently 
developed calcium phosphate cements appear to fulfil these requirements, 
because they support bone growth (osteoconductive), are degradable due 
to osteoclastic remodelling, are injectable, can incorporate microspheres 
and can be made micro/macroporous to allow nutrients and clearance of 
waste.21-26 Unfortunately, the results as obtained with the culturing of 
osteoblastic cells on CaP cements are contradictory. This can be due to the 
composition of the starting powder as used for the preparation of the CaP 
cement. For example, different calcium phosphate mixtures have been used, 
like tetracalciumphosphate, dicalciumphosphatedehydrate, calcium 
pyrophosphate, tricalciumphosphate, etc, which during setting transform into 
materials composed of hydroxyapatite, carbonated apatite and amorphous 
calcium phosphate. However, toxic substances can be released during this 
transformation process, which can be harmful during cell culturing. This effect 
can even be enhanced by e.g. the size or geometry of the cement samples, 
manufacturing conditions, cell media changes and total cell medium 
volume. Evidently, no problems have been observed for the in vivo behaviour 
of these CaP cement materials because the toxic products are sufficiently 
transported away during the initial phases of wound healing. At the same 
time, this phenomenon can explain the contradictory cell culture studies. For 
example, using a CaP cement denominated Calcibon (Merck Biomaterial 
GmbH, Darmstadt, Germany), Hempel et al. found a reduced cell 
proliferation and differentiation compared to polystyrene cultures. The CaP 
scaffolds in this study were preincubated in simulated body fluid for 4 days.27 
In contrast to Hempel et al., Oreffo et al. and Knabe et al. reported a 
reduced cell proliferation and increased cell differentiation on this material 
compared with polystyrene cultures. Oreffo et al. preincubated the CaP 
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scaffolds for 5 days in Ringer’s solution and Knabe et al. sterilized the scaffolds 
at 300°C for 3 hours.27-29  
Consequently, before the final use of CaP cement as scaffold material for a 
cell-based tissue engineering approach, the cytocompatibility of such a 
material has to be determined. In the current study, unmodified discs 
together with discs preincubated in MilliQ and discs sintered at different 
temperatures were used. These additional treatments can create phase 
transformations of the CaP cement, which can affect the cellular response. 
 
Materials and Methods 
Substrates: 
The CaP cement Calcibon® (Biomet Merck, Darmstadt, Germany) was used. 
The chemical composition of this cement is 61% α-TCP, 26% CaHPO4, 10% 
CaCO3 and 3% PHA (α-TCP is alpha tri-calcium phosphate, PHA is 
precipitated hydroxyapatite). An aqueous solution of 1% Na2HPO4 is used as 
the liquid component. The ideal liquid/powder ratio for clinical applications 
has been shown to be 0.35 ml/g. After mixing, the cement was immediately 
injected in a circular-shaped mould to ensure a standardized shape of the 
cements (cylinders of about 2.4 mm height and 6 mm diameter). The discs 
were removed from the molds after setting of the cement. The total 
microporosity of the cement was about 30-40%. Besides the unmodified CaP 
cement discs, samples were: 
1) preincubated (1, 4, 8 and 12 weeks) on a rotating plate in MilliQ, which 
was refreshed three times a week. 
2) sintered (600°C, 800°C, 1000°C or 1100°C) in a furnace for 2 hours at the 
designated temperature. 
The chemical composition of the samples was evaluated by X-ray diffraction 
(XRD, Philips PW3710, Eindhoven, The Netherlands) by crushing the samples 
with a mortar until the discs were reduced into powder. The positions and the 
intensities of the peaks were used for identifying the underlying structure (or 
phase) of the various treatments of the specimens. 
 
Cell isolation: 
Rat bone marrow (RBM) cells were isolated and cultured using the method 
described by Maniatopoulos.30 RBM cells were obtained from femora of male 
Wistar rats weighing between 120-150g. Femora were washed 3 times in 
culture medium α-MEM (Minimal Essential Medium; MEM Gibco BRL, Life 
Technologies B.V. Breda, The Netherlands) with 0.5 mg/ml gentamycin and 3 
μg/ml fungizone. Epiphyses were cut off and diaphyses flushed out with 15 ml 
complete culture medium α-MEM, supplemented with 10 % FCS (foetal calf 
serum, Gibco), 50 μg/ml ascorbic acid (Sigma, Chemical Co., St.Louis, MO, 
USA), 50 μg/ml gentamycin, 10 mM Na β-glycerophosphate (Sigma) and 10–8 
M dexamethasone (Sigma). Cells were incubated in a humidified atmosphere 
of 95 % air, 5 % CO2 at 37°C. The medium was changed three times a week. 
After 7 days of primary culture, cells were detached using trypsin/ EDTA (0.25% 
w/v trypsin / 0.02% EDTA). The cells were concentrated by centrifugation at 
1500 rpm for 5 minutes and resuspended in a known amount of media. Cells 
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were counted by a Coulter® counter (Beckman Coulter, Mijdrecht, The 
Netherlands) and resuspended in complete medium. The cell suspension 
(50.000 cells per disc) was used for the seeding and culturing experiments. 
 
Cell viability: 
Live & Dead viability assays (Molecular Probes, Leiden, The Netherlands) (n=2 
for all culture periods) were performed on day 0, 1, 2, 4, 8 and 12, consisting of 
washing with PBS, covering with a mix of calcein AM (1.0 μl) and ethidium 
homodimer (3.5 μl), incubating 30-45 minutes at 37°C, washing with PBS, and 
finally examining under the fluorescence microscope. Metabolically active 
cells were converting the calcein AM into green fluorescent calcein through 
intracellular esterases, where ethidium homodimer entered dead cells 
through damaged membranes to bind DNA. Green cells were viable and red 
cells are considered to be dead. 
 
DNA analyses: 
DNA assays (Molecular Probes, Leiden, The Netherlands) (n=6 for all culture 
periods) were performed on day 0, 1, 2, 4, 8 and 12. Culture medium was 
removed and discs were washed twice with PBS. 1 ml of MilliQ was added to 
each sample. Cells were harvested by placing the discs with inoculated cells 
in a 1.5 ml tube. 1 ml of MilliQ was added to each sample. Cell suspension 
was frozen to -80°C, heated to 37°C, frozen to -80°C again and stored at -
80°C until usage. 
DNA standard curve was made with Salmon testes DNA. 100 μl of sample or 
standard were added to 100 μl Picogreen working solution. The samples were 
incubated for 5 minutes at room temperature in the dark. After incubation, 
DNA was measured using a fluorescence microplate reader (Bio-Tek 
instruments, Abcoude, The Netherlands) with excitation filter 365 nm and 
emission filter 450 nm. 
 
Alkaline phosphatase activity (ALP): 
For the ALP assay (Sigma, Chemical Co., St. Louis, MO, USA), the same 
samples from the DNA assay were used. 80 μl of sample and 20 μl of buffer 
solution (5 mM MgCl2, 0.5M 2-amino-2methyl-1-propanol) were added in a 96-
well plate. 100 μl of substrate solution (5mM p-nitrophenylphosphate) was 
added to the well and the plate was incubated for 1 hour at 37°C. The 
reaction was stopped by adding 100 μl of stop solution (0.3 M NaOH). For the 
standard curve, serial dilutions of 4-nitrophenol were added to final 
concentrations of 0 to 25nM. The plate was read in an ELISA reader (Bio-Tek 
instruments, Abcoude, The Netherlands) at 405 nm. 
 
Scanning electron microscopy (SEM): 
SEM analyses (n=2 for all culture periods) was performed on day 0, 1, 2, 4, 8 
and 12. The samples were washed twice with PBS. Fixation was carried out for 
10 minutes in 2% glutaraldehyde, then substrates were washed twice with 0.1 
M sodium-cacodylate buffer (pH 7.4), dehydrated in a graded series of 
ethanol and drying by tetramethylsilane. The specimens were sputter-coated 
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with gold and examined and photographed using a Jeol 6310 SEM at an 
acceleration voltage of 10 kV. SEM was performed at the Microscopic 
Imaging Center (MIC) of the Nijmegen Center for Molecular Life Sciences 
(NCMLS), The Netherlands.  
 
Statistical analyses: 
Statistical analyses were performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using an one-way analyses of 
variance (ANOVA) with a Tukey multiple comparison post test.  
 
Results 
Unmodified Calcibon: 
The results of the XRD analyses (Figure 1) demonstrated that the unmodified 
CaP cement discs were mainly composed of α-TCP.  
 
 
Figure 1: X-ray diffraction analyses of the CaP cement discs. The XRD powder patterns of (A) 
unmodified, 1, 4, 8 and 12 weeks preincubated discs and  (B) unmodified, 600°C, 800°C, 
1000°C and 1100°C sintered discs are shown respectively. (* = apatite; # = β-TCP; + = α-TCP) 
 
 
Further, these samples caused a pH decrease of the culture medium, 
indicated by the change of color from red to yellowish. SEM pictures (Figure 
2A) revealed that cell layers detached from the disc surface. This started at 
day 1 and was observed throughout the entire culturing period. The number 
of cells present on the surface was also reduced over time. At day 8, only a 
few viable cells were observed on the disc surface with the Live & Dead assay 
(Figure 3A). The results of the DNA analyses (Figure 4) confirmed the results of 
Live & Dead and SEM by showing a reduced DNA content during time, 
ending at day 12 closely to zero. Almost no ALP activity (Figure 5) was 
measured during this culturing period. 
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Figure 2: Scanning Electron Microscopy (SEM) of (A) unmodified, (B) 1 week preincubated 
and (C) 1100°C sintered discs after day 1 of culture. 
 
 
Preincubated Calcibon: 
The results of the XRD (Figure 1A) demonstrated that preincubation of the CaP 
cement discs in MilliQ resulted in the hydrolysis of α-TCP into an apatite-like 
structure with some β-TCP. Further, these samples caused a pH decrease of 
the culture medium, indicated by the change of color from red to yellowish. 
The duration (1, 4, 8 or 12 weeks) of preincubation resulted in no changes in 
physicochemical properties. Cell attachment and viability results were 
comparable between the preincubation periods of 1, 4, 8 and 12 weeks (not 
shown). SEM examination (Figure 2B) revealed that cell layers were now only 
partially detaching from the disc surface and more cells were attached to 
the surface compared to unmodified samples. This was already observed at 
day 1, but also throughout the culturing period. However, Live & Dead assays 
(Figure 3B) displayed after 8 days still a reduced cell number, although the 
cells were well-spread on the surface of the discs. The DNA amount (Figure 4) 
remained at a constant level as at the start of the experiment, but the ALP 
activity (Figure 5) was close to zero. 
 
 
gure 3: Live & Dead assays of (A) unmodified, (B) 1 week preincubated and (C) 1100°C 
 
 
Fi
sintered discs after 8 days of culture. 
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Sintered Calcibon:   
gure 1B) demonstrated that the 600°C 
cal properties as the unmodified 
The results of the XRD analyses (Fi
sintered discs consisted of the same chemi
samples. However, sintering at 800°C, 1000°C and 1100°C resulted in 
conversion of α-TCP into β-TCP with some hydroxyapatite and in an increase 
of crystallinity. The 800°C samples (and in a lesser extent the 1000°C samples) 
caused a rapid pH increase of the culture medium, indicated by the change 
of color from red to pink. The results of the Live & Dead and SEM analyses 
showed that osteoblast-like cells were not able to survive on the 800°C 
sintered discs, where the cells on the 1000°C were still viable and proliferating. 
Nonetheless, the 1100°C sintered discs demonstrated superior cell attachment 
and viability throughout the culturing period of 12 days compared to the 
other sintering temperatures (600°C, 800°C, 1000°C) and preincubated and 
unmodified discs. This was confirmed by SEM examination (Figure 2C) showing 
well-spread cell layers, which were attached to the surface and by the results 
of Live & Dead analyses (Figure 3C) revealing the presence of live cells over 
the complete surface area of the discs. DNA results (Figure 4) showed that 
from day 4 the amount of DNA increased significantly compared to both 
preincubated and unmodified samples, and the difference increased even 
further after 8 and 12 days. Also, ALP activity (Figure 5) was observed and 
showed a bell-shaped curve for osteoblast differentiation with a peak activity 
at day 8. The ALP activity at day 4 was close to the peak activity at day 8, 
indicating an earlier differentiation of the osteoblast-like cells compared to 
regular osteoblast differentiation. The increase in ALP activity started already 
at day 1, also indicating an earlier differentiation of osteoblast-like cells. 
 
 
 
Figure 4: DNA (Picogreen) assay of unmodified, 1 week preincubated and 1100°C sintered 
iscs until 12 days of culture. Significant differences (P<0.05) are indicate  with a single d d
asterisk between preincubated and unmodified discs; a double asterisk indicated a 
significant difference (P<0.05) between 1100°C sintered discs with both preincubated and 
unmodified samples; a triple asterisk indicated a significant difference (P<0.05) between 
1100°C sintered discs with unmodified samples. 
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Figure 5: Alkaline Phosphatase (ALP) activity assay of unmodified, 1 week pre cubated and 
100°C sintered discs until 12 days of culture. 
iscussion 
cy in results of culturing cells on Calcibon CaP cement was the 
in
1
 
 
D
The discrepan
underlying justification for the current study with specimens receiving different 
additional treatments. Our results revealed that the unmodified specimens 
were releasing cytotoxic metabolites in the medium, creating an acidic 
environment for the osteoblast-like cells. As a consequence, the seeded cells 
were slowly dying and detached over time. 
Preincubation of the CaP cement discs in MilliQ changed the chemical 
properties of the material. The originally present α-TCP was hydrolysed within 
one week of preincubation into an apatite-like structure with some β-TCP. 
These preincubated samples showed some improvement in cell viability 
compared to the unmodified CaP cement, but the material was still 
suppressing cell proliferation and differentiation of the osteoblast-like cells. The 
increase of acidity of the cell culture medium, in combination with the 
dissolution and re-precipitation of calcium phosphate phases of the discs, was 
hampering the cell proliferation and differentiation of the osteoblast-like 
cells.31 
On the other hand, sintering the CaP cement discs between 800°C and 
1100°  C resulted in conversion of α-TCP to β-TCP with some hydroxyapatite 
and in an increase of crystallinity. The discs were sintered at a maximum 
temperature of 1100°C, otherwise the stable β-TCP would be transformed into 
a more reactive α-TCP again.32 The β-TCP phase of the sintered discs favours 
the cell proliferation and differentiation in vitro significantly, creating a good 
scaffold material to support osteogenesis. Remarkably, the medium of the 
800°C sintered discs turned rapidly basic, in which osteoblast-like cells were 
unable to survive. The pH increase was also observed in the medium of the 
1000°C sintered discs, but in a lesser extent. Eventually, the 1100°C discs were 
the most physicochemically stable, resulting in the best cellular response of 
osteoblast-like cells compared to other sintering temperatures, preincubated 
34 
and unmodified samples.33  
As mentioned before, different results have been reported about the cell 
proliferation and cell differentiation of osteoblasts-like cells when cultured on 
s does not hamper the final in vivo behaviour of the material, 
n basis of our results, we conclude that in vivo results with CaP based 
 guarantee their in vitro applicability. Further, unmodified 
l at 
 
 
Calcibon.27-29,34 For example, Hempel et al. described that the toxic effects of 
the unmodified CaP cement are due to physicochemically unstable discs 
and released phosphate and protons into the culture medium resulting in a 
decrease in pH and an uptake of calcium by the specimens.29 The decrease 
in pH was also observed in our experiments with the unmodified and 
preincubated samples, which was reported to affect cell attachment and 
behaviour of the osteoblast-like cells in vitro.35-37 The alteration of the pH in the 
culture medium was illustrated by its changed color, which went from red to 
yellowish. This effect is the consequence of the presence of pH indicators in 
the α-MEM solution. In contrast to Hempel et al., Oreffo et al. and Knabe et al. 
reported a reduced cell proliferation and increased cell differentiation on 
Calcibon compared with polystyrene cultures. However, they were still able to 
culture the cells for an extended period.27,28 Our results are showing an 
reduced number of cells on unmodified specimens over time. The alteration in 
pH and extracellular concentrations of calcium and phosphate were 
described to cause considerable stress for the osteoblast-like cells and 
ultimately resulted in severely limited cell growth and differentiation.29 It was 
reported that this can be avoided by refreshing the media daily, instead of 
each 2-3 days. In this way, cell viability can be maintained and cell 
proliferation and differentiation of the osteoblast-like cells improved.38  
Besides, the decrease in pH and the uptake of calcium by the specimens, the 
negative effects on osteoblast-like cells could be due to the particle size of 
the CaP cement. Pioletti et al. described that CaP cement particles smaller 
than 10 µm have an effect on the viability and the proliferation of osteoblast-
like cells.39 
Evidently, the observed acidity of Calcibon CaP cement in in vitro cell culture 
experiment
because in vivo studies with Calcibon21,23,40 are describing excellent bone 
compatibility as characterized by the fast deposition of new bone on the 
cement surface, which proves that the material is extremely osteoconductive 
and suitable for clinical purposes. This emphasizes that in vitro cell studies can 
not be extrapolated implicit to the in vivo situation, which is described by 
Rosengren at al. who found that an initially cytotoxic scaffold in vitro could, in 
a long-term perspective, become biocompatible in vivo.41  
 
Conclusions 
O
cements do not
Calcibon is not cytocompatible in vitro, although preincubation of the 
material results in a more favourable cell response, sintering of the materia
1100°C is resulting in the best osteogenic properties. In contrast to in vivo
studies, the Calcibon CaP cement is not suitable as a scaffold for cell-based 
tissue-engineering strategies.  
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Introduction 
The filling of bone defects resulting from trauma or surgical resection of tumors 
requires the availability of safe and reliable synthetic bone substitutes, since 
obtaining autologous bone is accompanied with the known disadvantages 
of donor site morbidity, increased operative time, and insufficient volumes. 
Calcium phosphate (CaP) cements have been proven to be useful as bone 
substitutes.1-4 Previous work on CaP cement has shown that if it consists of a 
mixture of powder and liquid, this CaP cement becomes injectable, and 
hence can be shaped perfectly according to the defect dimension in situ.5-8 
Porosity can be created by incorporating degradable poly (D,L-lactic-co-
glycolic acid) (PLGA) microparticles in the CaP cement to enhance tissue 
ingrowth in the CaP cement.9,10 PLGA microparticles will be hydrolyzed in vivo 
and as a consequence create microporosity. PLGA polymers are interesting 
due to degradation properties, which can be tailored by changing molecular 
weight, tacticity, and lactic to glycolic ratio.11 Although, a previous study with 
various small-sized CaP/PLGA composite implants (0, 15, 30 or 50% w/w PLGA 
microparticles) showed an excellent bone response12, additional studies to 
the biocompatibility of CaP/PLGA implants have to be performed to exclude 
that the incorporated PLGA microparticles evoke an inflammatory response 
during their degradation. In the design of such an experiment, it has to be 
included that PLGA microparticle size can affect the foreign body reaction at 
the surface of the microparticles.13 Also, by varying the amounts and 
diameter sizes of PLGA microparticles a threshold for interconnectivity can be 
determined. Furthermore, these PLGA microparticles can be loaded with 
growth factors to stimulate bone formation and cement resorption in future 
applications.14,15 
Also, the biocompatibility of CaP cement could be improved by 
preincubation in water. Previous research resulted in a better cellular response 
after preincubation in vitro11, which could also have an effect on the final in 
vivo tissue response. 
In view of the above mentioned, this study focused at the biocompatibility of 
CaP cement incorporating PLGA microparticles in a subcutaneous 
implantation model in rats. Short-term biocompatibility was assessed using 
CaP discs and CaP discs incorporating PLGA microparticles (20% w/w) with 
and without preincubation in water. Long-term biocompatibility was assessed 
using CaP discs incorporating various amounts (5, 10, or 20% w/w) and 
diameter sizes (small, 0-50 μm; medium, 51-100 μm, or large, 101-200 μm) of 
PLGA microparticles. 
 
Materials & Methods 
Substrates 
The CaP cement Calcibon® (Biomet Merck, Darmstadt, Germany) was used, 
which has a chemical composition of 61% α-TCP, 26% CaHPO4, 10% CaCO3 
and 3% PHA (α-TCP is alpha tri-calcium phosphate, PHA is precipitated 
hydroxyapatite). An aqueous solution of 1% Na2HPO4 was used as the liquid 
component. The used liquid/powder ratio was 0.35 ml/g. Before usage, the 
cement powder was sterilized by γ-radiation with 25 kGy (Isotron B.V., Ede, 
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The Netherlands) The cement liquid was filter-sterilized though a sterile 0.2 µm 
filter. 
 
PLGA microparticles 
PLGA (Purasorb®, Purac, Gorinchem, The Netherlands) with a molecular 
weight of 48 kDa and a lactic to glycolic acid ratio of 50:50 was used. PLGA 
microparticles were prepared using a (water/oil/water) double emulsion 
solvent evaporation technique. The microparticles were produced by solving 
1.0 g PLGA in 4 ml of dichloromethane (DCM) inside a glass tube. After 
dissolution, 500 µl deionized water was added to this mixture and emulsified 
for 60 seconds on a vortexer. Subsequently, 6 ml 0.3% aqueous poly vinyl 
alcohol (PVA) solution was added and vortexed for another 60 seconds to 
produce the second emulsion. After vortexing, the content of the glass tube 
was transferred to a 1000 ml beaker and another 394 ml of 0.3% PVA was 
added slowly under continuous stirring. This was directly followed by adding 
400 ml of a 2% isopropylic alcohol (IPA) solution. The suspension was stirred for 
one hour. After stirring, the microparticles were allowed to settle for 15 minutes 
and the solution was decanted. The microparticle suspension was 
centrifuged, and the clear solution at the top was decanted. Then 5 ml of 
deionized water was added, the microparticles were washed, centrifuged 
and the solution was aspirated. Finally, the microparticles were frozen, freeze-
dried for 24 hours and stored under argon at -20°C. For the short-term 
biocompatibility study, PLGA microparticles ranging from 5 to 120 μm were 
used with an average diameter of 33 μm. For the long-term biocompatibility 
study, microparticles were sieved with a sieve shaker (Retsch GmbH, Haan, 
Germany) with 50, 100 and 200 μm diameter sieves to obtain batches of small 
(0-50 μm), medium (51-100 μm), and large (101-200 μm) PLGA microparticles. 
 
Pre-set sample preparation 
The discs were prepared by adding 350 μl cement liquid (1% w/w aqueous 
solution of Na2HPO4) to a 1000 mg CaP cement powder or CaP/PLGA mixture 
in a 2 ml syringe (Becton Dickinson, Alphen a/d Rijn, The Netherlands). The 
syringe was closed with an injection plunger and placed in a mixing 
apparatus (Silamat, Ivoclar Vivadent AG, Schaan, Liechtenstein). After mixing 
for 15 seconds, the plunger was removed and the cement/composite was 
injected in teflon moulds to ensure a standardized shape of the specimens. 
The discs (2.4 mm height and 6 mm diameter) were removed from the moulds 
after setting of the cement at room temperature. Discs were used without 
(CaP0) and with (CaP8) preincubation in water (8 weeks immersion on a 
rotating plate with water, refreshing 3 times a week at room temperature). 
 
CaP/PLGA microparticle composites 
Various CaP/PLGA composites were created by adding PLGA microparticles 
to the CaP cement. CaP cement composites with 5, 10 or 20% w/w PLGA and 
small, medium, or large microparticle diameter sizes were prepared (Table 1).  
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Table 1: Overview of the CaP/PLGA 
disc formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
The total porosity of the different CaP/PLGA composites was determined by 
correlating the weight of CaP discs with the weight of CaP/PLGA discs after 
placement of the samples in a furnace at 650°C for 2 hours to remove the 
PLGA microparticles.16 Afterwards, samples were analyzed using 
microcomputed tomography (µCT) (SkyScan 1172 high-resolution micro-CT, 
SkyScan, Kontich, Belgium). Also, the chemical composition of the samples 
was evaluated by crushing the samples with a mortar, until the discs were 
reduced to powder. The powder was then analyzed by using X-ray diffraction 
at room termperature (XRD, Philips PW3710, Eindhoven, the Netherlands). The 
positions and intensities of the XRD peaks were used to identify the underlying 
structure (phase) of the samples. 
 
Implantation 
Fifty-two male Wistar rats (100-120 g) were used for subcutaneous 
implantation. The rats received four implants each, two on each side of the 
vertical column. Short-term biocompatibility was assessed using four different 
implants (n=6) with variation in implant composition and preincubation (Table 
1), and implantation periods of 2, 4, 8 and 12 days. Long-term 
biocompatibility was assessed using nine different implants (n=6) with 
variation in PLGA microparticle amount and size (Table 1), and implantation 
periods of 12 and 24 weeks. 
Surgery was performed under general inhalation anesthesia with a 
combination of isoflurane, nitrous oxide and oxygen. For reasons of reliability, 
implant randomization was applied regarding location. To insert the implants, 
the animals were immobilized and placed in a ventral position. The back of 
the animals was shaved, washed and desinfected with povidone-iodine. 
Subsequently, four small longitudinal incisions (two on each site of the 
vertebral column) were made. Lateral to each incision, a subcutaneous 
pocket was created using blunt dissection. After placement of the implants, 
the skin was closed using staples (Agraven®, InstruVet BV, Cuijk, the 
Netherlands). At the end of each implantation period, the rats were sacrificed 
using CO2-suffication. 
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Histology 
Implants with surrounding tissue were retrieved and prepared for histological 
evaluation. The samples were fixed in 4% formalin solution (pH=7.4), 
dehydrated in a graded series of ethanol and embedded in 
methylmethacrylate. Following polymerization, 10 µm thick sections were 
prepared using a sawing microtome technique.17 The sections were stained 
with methylene blue and basic fuchsin and investigated with a light 
microscope to examine the amount of tissue inflammation or bone formation.  
 
 
Figure 1. Schematic drawing of a 
CaP/PLGA implant showing the 4 
predetermined areas used in the 
histological evaluation. 
 
 
 
 
The quantitative evaluation of the fibrous capsule was done in four 
predetermined fields using a histological grading scale for soft-tissue implants 
(Figure 1 and Table 2).18 The presented data represent the average of these 
four measurements. 
 
 
 
Table 2. Histological grading scale for soft-tissue implants. 
 
 
Statistical analyses 
Statistical analyses were performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using a one-way analysis of 
variance (ANOVA) with a post-hoc Tukey multiple comparisons test.  
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Results 
Implant characterization 
The microporosity of the various implant formulations varied between 6.5% 
and 57.1 %, showing lowest values for implants containing 5% PLGA small-sized 
and highest values for implants containing 20% PLGA large-sized 
microparticles (Figure 2).  
 
Figure 2. Microporosity (in %) of the 
different implant formulations. The 
20% PLGA 0-200 µm sizes were used 
for the early implantation periods 
(short-term biocompatibility) 
(CaP0/PGLA and CaP8/PLGA). All 
other formulations were used for 12 
and 24 weeks implantation 
(longterm-biocompatibility) 
 
 
 
 
XRD analysis demonstrated that the CaP0 discs were mainly composed of α-
tri calcium phosphate (α-TCP). Preincubation of the discs for eight weeks in 
water (CaP8) resulted in the hydrolysis of α-TCP into an apatite-like structure 
with some β-TCP. After implantation, the structure of the CaP8 samples 
remained the same, whereas the CaP0 samples underwent hydrolysis of α-
TCP into an apatite-like structure without β-TCP formation (Figure 3). The 
incorporation of PLGA microparticles did not induce alterations of XRD 
patterns compared to pure CaP samples. 
 
Figure 3. X-ray diffraction (XRD) 
patterns of the calcium phosphate 
cement discs. The XRD powder 
patterns of as-prepared (CaP0) 
and pre-incubated discs (CaP8), 
both before and after 
subcutaneous implantation for 12 
days. (* = apatite; # = β-tri calcium 
phosphate (TCP); + = α-TCP) 
 
 
 
 
 
 
Microcomputed tomography (µCT) indicated interconnectivity within all 
samples containing 20% (w/w) PLGA, except for those with small diameter (0-
50 μm) microparticles (Figure 4). 
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Figure 4. Microcomputed tomography (µCT) images of CaP implants containing 5% (A), 10% 
(B), 20% (C) PLGA 101-200 µm sizes. Together with 20% PLGA 0-200 µm sizes (D) used for the 
early implantation periods (short-term biocompatibility). PLGA microparticles appear as pores 
in the CaP cement. The size of each sample is 0.5 x 0.5 x 0.5 mm. 
 
 
In vivo studies 
All fifty-two rats in this experiment remained in good health and did not show 
any wound complications. At retrieval, the 12 and 24 week implants were 
surrounded by a macroscopically visible fibrous capsule. All implants had 
retained their structural integrity, and no inflammatory signs or adverse tissue 
reactions were observed. 
 
Short-term biocompatibility 
Light microscopic analysis of the histological sections revealed that a fibrous 
tissue capsule developed around all implants in time. Furthermore, 
inflammatory cells were present during all implantation periods (2, 4, 8 and 12 
days), but amounts were declining in time. No multinucleated cells were 
observed within any of the different implant formulations (CaP0, CaP0/PLGA, 
CaP8 and CaP8/PLGA). CaP/PLGA cements, whether or not preincubated in 
water, did not contain fibrous tissue throughout the implants, but only 
concavities on the surface of the implants were filled with fibrous tissue. 
After 2 days of implantation, inflammatory cells were observed in the implant 
vicinity without a connective tissue capsule around any of the implants. After 
4 days (Figure 5A,B), a thin connective tissue capsule had developed, 
containing inflammatory cells with some fibroblasts and a small amount of 
collagen bundles. After 8 days, the amount of collagen and number of 
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fibroblasts increased in the thin connective tissue capsule and still few 
inflammatory cells were present. At 12 days (Figure 5C,D), the thin fibrous 
capsule had not increased in size and the amount of fibroblasts and 
inflammatory cells appeared to be similar as for the 8 days implants. 
 
 
Figure 5. Histological sections of 
CaP implants containing 20% PLGA 
microparticles after 4 days (A and 
B) and 12 days (C and D) of 
implantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative histological evaluation (Figure 6) revealed that no significant 
differences in capsule and interface scores were present between the 
different formulations of implants (CaP0, CaP0/PLGA, CaP8 and CaP8/PLGA) 
at individual time points. On the other hand, capsule quality scores of the 
CaP0 and CaP8/PLGA group were significantly different between 4 and 12 
days, both showing the transformation of a granulous and dense capsule 
containing fibroblasts and inflammatory cells into a mature capsule 
resembling connective tissue (Figure 6A). Furthermore, capsule quantity 
scores of the CaP8/PLGA group between 4 and 8 days were significantly 
different, showing an increase in the number of fibroblast layers from 1-4 at 
day 4 to 5-9 fibroblast layers at day 8 (Figure 6B). Finally, capsule interface 
scores were significantly different between days 4 and 12 in the CaP0/PLGA 
group, where inflammatory cells contacting the surface of the implants were 
replaced by fibroblasts (Figure 6C).  
 
46 
 
 
Figure 6. Histological evaluation of capsule quality (A), capsule quantity (B) and interface 
quality (C) of the short-term biocompatibility samples using the histological grading scale. 
Data shown represent mean ± sd. Significant differences (p<0.05) are indicated with an 
asterisk (*). 
 
 
Long-term biocompatibility 
All implant formulations (CaP with 5, 10 or 20% w/w PLGA and small, medium, 
or large microparticle sizes) were surrounded by a connective tissue capsule 
containing fibroblasts, collagen bundles and few inflammatory cells after 12 
weeks of implantation (Figure 7). No multinucleated cells were observed 
within any of the different implant formulations. Similar observations were 
made after 24 weeks of implantation. Furthermore, only few inflammatory 
cells were present in the pores of the implants, which were created after 
hydrolysis of PLGA microparticles. The implants containing 20% PLGA with 
medium- and large-sized microparticles showed fibrous tissue ingrowth 
throughout the implants (Figure 7C,D), indicating PLGA degradation and 
interconnectivity of the pores. This is in contrast to all 5% and 10% PLGA 
formulations, and 20% PLGA formulations with small-sized microparticles, 
which only showed fibrous tissue ingrowth at the implant periphery. 
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Figure 7. Histological sections of 
CaP implants containing 10% 
PLGA 101-200 µm sizes (A and B) 
and 20% PLGA 51-100 µm sizes (C 
and D) after 24 weeks of 
implantation. Arrows indicate 
fibrous tissue ingrowth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative histological evaluation revealed that no significant differences in 
capsule and interface scores were present between the different implant 
formulations (CaP with 5, 10 or 20% w/w PLGA and small, medium, or large 
microparticle sizes) at individual time points (Figure 8). 
 
 
 
 
Figure 8. Histological evaluation of capsule quality (A), capsule quantity (B), and interface 
quality (C) of the long-term biocompatibility samples using the histological grading scale. 
Data shown represent mean ± sd. 
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Discussion 
This biocompatibility study was performed to exclude that the incorporated 
PLGA microparticles evoked an inflammatory response. Therefore, the short 
and long-term biocompatibility of CaP/PLGA formulations was examined 
using a subcutaneous implantation model in rats.  
Physicochemical analysis demonstrated that due to implantation or 
preincubation in water, the α-TCP component in the CaP cement undergoes 
hydrolysis resulting in transformation into an apatite-like structure. After 
implantation, CaP cement hydrolysis was more pronounced in preincubated 
samples compared to non-preincubated samples. This might be due to a 
longer exposure time (8 weeks) of preincubated samples to water, the 
difference between body fluids and only water, or a combination of both. 
Histological and histomorphometrical evaluation showed only a mild tissue 
response to any of the different CaP/PLGA composites formulations in the 
early implantation periods (2, 4, 8, and 12 days). No differences in vivo were 
observed between pure CaP cement and CaP cement incorporating PLGA 
microparticles, whether or not preincubated in water. Implant preincubation 
was based on the results of a previous in vitro study13, which showed that 
without preincubation in water, CaP cement was not physicochemically 
stable. This resulted in the release of ionic species, which caused cell death. 
The preincubation of CaP cement resulted in the hydrolysis of α-TCP into an 
apatite-like structure, which favored the biological response. However, the 
preincubated CaP cement still was not cytocompatible in vitro.13 
Nevertheless, the in vivo results of the current study did not indicate a 
detrimental effect of formulations without preincubation on cells/tissues. 
Apparently, the capacity to buffer ionic species in vivo is higher than in in vitro 
experiments. Although PLGA is regarded as a non-toxic and biocompatible 
material19, it is known that PLGA microparticles larger than 10 micron in 
diameter can evoke a foreign body reaction at the surface of these 
microparticles.11,20 These data do not confirm the results of the current study, 
as no inflammatory response to PLGA microparticles was observed with 
various (1-200 µm).   
The microporosity in the CaP cement was created by incorporation and 
subsequent in vivo hydrolysis of PLGA microparticles. However, incorporation 
of microparticles is not a guarantee to achieve interconnectivity in the 
composites. In the present study, fibrous tissue ingrowth after 24 weeks 
throughout the implant indicated complete PLGA degradation and 
interconnectivity in the formulations containing 20% PLGA with medium and 
large microparticles. Recently, Habraken et al. showed that in vitro 
degradation of PLGA microparticles started after 6 weeks and was 
completed after 12 weeks. However, the reduction in molecular weight of the 
PLGA already started at day 0 and was 80% at 6 weeks when mass loss was 
visible.16 Therefore, the PLGA microparticles encapsulated in the CaP cement 
maintained their structure until 6 weeks, although molecular weight loss 
already commenced. In the current study, complete degradation of PLGA 
microparticles could only be evidenced by fibrous tissue ingrowth throughout 
the implants after 12 and 24 weeks.  
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Interestingly, in the implants containing 10% w/w PLGA with large 
microparticles, no fibrous tissue inside the implants was observed. This might 
indicate that within this CaP/PLGA formulation the micropores were not 
interconnected. However, the porosity of 50.1 ± 0.7% in these implants was 
higher compared to the 36.2 ± 1.9% porosity of in the implants with 20% PLGA 
with medium microparticles. This suggests that interconnectivity does not 
depend solely on larger particles, but also on smaller particles as a 
connecting agent. The most ideal might be a mixture of smaller and larger 
microparticles, where smaller particles can act as a connecting agent 
between the larger particles to create an interconnected network. The 
interconnectivity in the composites with 20% PLGA with medium and large 
microparticles corroborates other studies indicating the necessity of pores of 
at least 50 μm to obtain optimal porosity of porous ceramics.21 
Microcomputed tomography also indicated interconnectivity between the 
samples of 20% PLGA with medium and large sized microparticles. By 
applying a threshold to the images, the CaP cement was extracted form the 
original image. Due to reasons of arbitrary threshold as a result of alternating 
ranges and intensities of individual sample grey scales, µCT was not 
applicable for quantification of porosity and interconnectivity.22,23 Therefore, 
µCT was only used to visualize the appearance of the samples. 
Remarkably, a study by Ruhé et al. indicated that CaP cement possesses a 
certain degree of intrinsic osteoinductive properties, as they found 
mineralized extracellular matrix in pores after PLGA degradation10. However, 
that study consisted of smaller CaP/PLGA implants (2.0 mm height and 3.5 
mm diameter) together with larger PLGA microparticles (73 ± 27 µm) 
combined with CO2 induced macropores, which together gave a 
heterogeneous distribution of macropores. Although, the current study was 
not designed to examine possible osteoinductivity of CaP cement, none of 
the composite formulations showed any formation of bone upon 
subcutaneous implantation. However, these observations do not exclude 
osteoinductive properties of CaP cement, since factors like species, implant 
location and implant size are known to influence the formation of bone tissue 
at ectopic sites.24,25  
 
Conclusions 
The results of the present study demonstrate that CaP/PLGA composites 
evoke a minimal inflammatory response. The implants containing 20% PLGA 
with medium- and large-sized microparticles showed fibrous tissue ingrowth 
throughout the implants after 12 and 24 weeks indicating PLGA degradation 
and interconnectivity of the pores. Therefore, CaP/PLGA composites can be 
regarded as biocompatible biomaterials with huge potential for bone tissue 
engineering and advantageous possibilities of the microparticles regarding 
material porosity and drug delivery. 
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Introduction 
Calcium Phosphate (CaP) ceramics are widely used as bone substitutes in 
dentistry, orthopedics and reconstructive surgery, because of their 
biocompatibility and osteoconductivity. Unfortunately, these ceramics are 
only available as prefabricated blocks or granules. Prefabricated blocks are 
difficult to shape, resulting in poor filling of the bone defect, while granules do 
not provide the dimensional stability and can easily migrate into the 
surrounding tissue. A solution for these problems can be CaP cement that can 
be shaped according to the defect dimension and harden in situ.1-9 The 
injectable CaP cement as used in this study consists of a mixture of powder 
and liquid. The formed paste hardens in situ as a result of the entanglement of 
the newly formed crystals at body temperature. These cements are highly 
compatible with soft and hard tissues because of the apatitic nature of the 
setting reaction products. However, calcium phosphate ceramics are known 
as slowly biodegradable materials. Therefore, methods have been developed 
to enhance tissue ingrowth and degradation rate by increasing the porosity 
of the ceramics. Consequently, the creation of macroporosity in CaP cement 
will increase the degradation of the CaP cement as well as the ingrowth of 
new bone tissue into the cement porosity.10-12 In view of this, a method was 
developed to prepare cement composites, in which poly (D,L-lactic-co-
glycolic) acid (PLGA) microparticles were incorporated. The microparticles 
will be hydrolysed in vivo and as a consequence create macroporosity. 
However, the in vivo degradation rate of the PLGA microparticles depends 
on the physicochemical properties such as molecular weight, particle size 
and structure.13 Therefore, the inclusion of PLGA microparticles into CaP 
cement will result in increased macroporosity after degradation of the 
particles. The degradation rate of the microparticles is generally faster than 
the surrounding CaP cement. Additionally, the incorporation of degradable 
microparticles can be used to allow drug and growth factor delivery.14-15   
In vitro research on the mechanical properties of highly porous 
biodegradable cement composites by others showed compressive strength 
and a modulus of elasticity comparable to trabecular bone.16-27 On the other 
hand, a previous study by Ruhé et al. on the mechanical strength of 
CaP/PLGA cement composite scaffolds in vitro showed that the initial 
strength of this composite scaffold is significantly lower than for CaP cement 
alone.14 The creation of porosity is associated with a loss in mechanical 
strength of the cement material; this appears to make the material less 
suitable for use under loaded conditions. Alternatively, the initial decrease in 
mechanical strength could be compensated by the excellent bone 
biocompatibility of the material. This allows a fast ingrowth of bone into the 
cement porosity. 
Therefore, the aim of our study is to prove that bone ingrowth results in an 
increase of mechanical strength of the macroporous cement. 
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Materials en methods 
Substrates: 
CaP cement (Calcibon®, Biomet Merck, Darmstadt, Germany) was used for 
the preparation of the implants. The chemical composition of this cement is 
61% α-TCP, 26% CaHPO4, 10% CaCO3 and 3% PHA (α-TCP is α tri-calcium 
phosphate, PHA is precipitated hydroxyapatite). An aqueous solution of 1% 
Na2HPO4 was used as the liquid component. The ideal liquid/powder ratio for 
clinical applications has shown to be 0.35 ml/g. Before usage, the cement 
powder was sterilized by gamma radiation with 25 kGy (Isotron B.V., Ede, The 
Netherlands). The cement liquid was filter-sterilized through a sterile 0.2 μm 
filter. 
 
PLGA microparticles: 
PLGA (Purasorb®, Purac, Gorinchem, The Netherlands) microparticles were 
prepared using a (water/oil/water) double emulsion solvent evaporation 
technique. The microparticles were produced by solving 1.0 g PLGA in 4 ml of 
dichloromethane (DCM) inside a glass tube. After dissolution, 500 µl MilliQ was 
added to this mixture and emulsified for 60 seconds on a vortexer. 
Subsequently, 6 ml 0.3% aqueous poly(vinyl alcohol) (PVA) solution was 
added and vortexed for another 60 seconds to produce the second 
emulsion. After vortexing, the content of the glass tube was transferred to a 
stirred 1000 ml beaker and another 394 ml of 0.3% PVA was added slowly. This 
was directly followed by adding 400 ml of a 2% isopropylic alcohol (IPA) 
solution. The suspension was stirred for one hour. After stirring, the 
microparticles were allowed to settle for 15 minutes and the solution was 
decanted. The suspension left was centrifuged, and the clear solution at the 
top was decanted. Then 5 ml of MilliQ was added, the microparticles were 
washed, centrifuged and the solution was aspirated. Finally, the 
microparticles were frozen, freeze-dried for 24 hours and stored under argon 
at -20°C. 
 
CaP/PLGA microparticle composites: 
CaP/PLGA composites were prepared by adding PLGA microparticles to the 
CaP cement powder in a weight ratio of 20% to 80% respectively. Then, 350 μl 
cement liquid (1 wt% aqueous solution of Na2HPO4) was added to 1000 mg of 
the CaP/PLGA mixture in a 2 ml syringe (Becton Dickinson, Alphen a/d Rijn, 
The Netherlands). The syringe was closed with an injection plunger and 
placed in a mixing apparatus (Silamat, Ivoclar Vivadent AG, Schaan, 
Liechtenstein). After mixing for 15 seconds, the plunger was removed and the 
composite was injected in teflon moulds to ensure a standardized shape of 
the specimens. The discs (5 mm in diameter and 2 mm in height) were 
removed from the moulds after setting of the cement at 37°C for one hour.  
 
Surgery: 
Twenty-four male Wistar rats (250 g) were used for a cranial study. Each rat 
received one implant. The implantation periods were 2, 4, and 8 weeks 
respectively (n=8 for all implantation periods). National guidelines for the care 
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and use of laboratory animals were respected. Surgery was performed under 
general inhalation anesthesia induced by 5% isoflurane, and maintained with 
2.5% isoflurane by a non-rebreather mask. The rats were monitored with an 
oxy-pulse meter during surgery. To minimize postoperative pain, Fentanyl® (3 
ml/kg i.p.) was administered preoperatively and buprenorfine (Temgesic®) 
(0.05 mg/kg s.c.) for two days postoperatively.  
After anesthesia, the rats were immobilized on their abdomen and the skull 
was shaved and disinfected with povidone-iodine. A longitudinal incision was 
made down to the periosteum from the nasal bone to the occipital 
protuberance, and soft tissues were sharp-dissected to visualize the cranial 
periosteum. Subsequently, a midline incision was made in the periosteum, and 
the periosteum was undermined and lifted off the parietal skull. The pain was 
minimized by dripping lidocaine at the periosteum before incision. A full 
thickness bone defect was created in the parietal cranium, left of the sagittal 
suture, to avoid complications with the sagittal sinus. A hollow trephine bur 
(ACE Dental Implant Systems, Portugal) with an outer diameter of 5.1 mm in a 
dental handpiece was used to create the defect. The bone defect was 
carefully drilled under continuous cooling with physiologic saline and without 
damaging of the underlying dura. After that, the created bone segment was 
carefully removed. Following insertion of the implants, the periosteum was 
closed using non-resorbable Prolene® 5-0 suture material. Subsequently, skin 
was closed using resorbable Vicryl® 4-0 sutures.  
The animals were housed individually in cages. The proper intake of fluids and 
food was monitored during the first five days post-operatively. Further, the 
animals were observed for signs of pain, infection and proper activity. After 2, 
4 or 8 weeks of surgery rats were sacrificed by an overdose of CO2. 
 
Mechanical testing, i.e.push-out test: 
To determine the shear strength of the porous implants after 2, 4 and 8 weeks 
of implantation, a push out-test (Dhert et al.32,33) was performed in a 
mechanical testing bench (MTS 858 Mini Bionix II, Gouda, The Netherlands). 
After sacrificing, the implants with their surrounding tissue were retrieved and 
transported to the laboratory in PBS on ice. Subsequently, each specimen 
was fixated on a support jig with a hole 0.4 mm larger than the implant 
diameter (5.1 mm) to minimize the effect of the test condition on the push-out 
results. This support jig enabled the application of a vertical force (at a 
constant displacement speed of 0.5 mm/min) on the CaP/PLGA discs. When 
the peak force was reached (representing implant loosening), the test was 
immediately stopped to ensure minimal displacement of the disc. The shear 
strength of the bone-cement interface was calculated by dividing the push-
out force (N) by π (pi) times the disc diameter (mm) times the cranial 
thickness (mm). 
 
Scanning electron microscopy (SEM): 
Following the push-out test, specimens were fixed in 10% formalin solution, 
dehydrated in a graded series of ethanol, and embedded in epoxy resin 
(Epofix®, Struers, Rødovre, Denmark). After polishing, the specimens were 
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sputter-coated with gold, and examined with SEM (Jeol 6310 Scanning 
Electron Microscope, Boston, MA, USA) to determine the fracture plane of the 
mechanically tested implants (e.g. in the cement, at the interface bone-
cement, in the surrounding bone). SEM was performed at the Microscopic 
Imaging Center (MIC) of the Nijmegen Center for Molecular Life Sciences 
(NCMLS), The Netherlands. 
 
Histology: 
After SEM examination, 10 µm-thick sections were prepared of the specimens 
embedded in epoxy resin in a direction transverse to the implant his axis using 
a sawing microtome technique. The sections were stained with methylene 
blue and basic fuchsin, and investigated with a light microscope (Leica 
Microsystems AG, Wetzlar, Germany) to examine the bone-cement interface 
and possible bone ingrowth. 
 
Statistical analyses: 
Statistical analyses were performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using an one-way analyses of 
variance (ANOVA) with a Tukey multiple comparison post test.  
 
 
Figure 1: Box-Whisker plot of the push-out results 
from the two, four and eight week implantation 
periods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Push-out test: 
The results of the push-out test (Figure 1) demonstrated that after two weeks 
of implantation the push-out values ranged from 0.18 to 1.28 MPa, which 
increased from 0.37 to 3.12 MPa at four weeks and finally got to a range 
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varying from 0.21 to 8.12 MPa. Calculating these push-out results into the 
shear strength of the bone-cement interface resulted in averages of 0.44 ± 
0.44 MPa at two weeks, which increased to 1.34 ± 1.05 MPa at four weeks and 
finally resulted in 2.60 ± 2.78 MPa at eight weeks. However, the differences 
between the three implantation groups were not significant. 
 
SEM examination: 
SEM examination (Figure 2A) showed a fracture plane at the bone-cement 
interface at two weeks. The four week implants showed a fracture plane, 
which was found at the bone-cement interface and into the CaP/PLGA 
composites as well (Figure 2B). The eight week implants demonstrated only 
fractures throughout the CaP/PLGA composites (Figure 2C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: SEM examination of a two (A), four (B) and eight (C) week implantation period 
respectively. CaP = calcium phosphate cement; B = cranial bone; D = degradated PLGA 
microparticle; F = fracture plane; I = bone-cement interface; N = newly formed bone; P = 
PLGA microparticle 
 
 
Histology: 
Histological evaluation (Figure 3A,B) showed that the two weeks implantation 
period resulted in minimal bone ingrowth from the cranial bone into the 
implants. At four weeks of implantation, the peripheral PLGA microparticles 
were degraded and replaced by newly formed bone. Further, a small layer of 
bone was present at the cerebral side of the implants. Fibrous tissue was 
observed between the cranial bone and the CaP/PLGA composites, 
especially when no close contact of cranial bone with the implant was 
observed. After eight weeks of implantation, almost all PLGA microparticles 
were degraded and bone deposition was observed throughout the 
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composites. The CaP cement was starting to degrade as indicated by loss of 
integrity of the implant and by the replacement of the cement with newly 
formed bone (Figure 3C,D). Nonetheless, not all of the implants showed good 
bone ingrowth, some implants showed fibrous tissue between the cranial 
bone with the CaP/PLGA composites when no close contact between bone 
and implant was observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Histology of a two (A and B) and eight (C and D) week implantation period 
respectively. B = cranial bone; I = bone-cement interface (filled with fibrous tissue); N = newly 
formed bone 
 
 
Discussion 
FDA regulations concerning medical devices state that bone fillers should be 
investigated on their mechanical properties to gain approval for clinical 
usage. The biomechanical testing should demonstrate the quality of the 
newly formed bone (Class II Special Controls Guidance Document: Dental 
Bone Grafting Material Devices) Therefore, a push-out test was used to 
evaluate the shear strength of the bone-cement interface. Results of the 
push-out test showed that shear strength of the implants increased during the 
eight weeks implantation period. The eight week specimens with the highest 
shear strength still maintained the bone-cement bond, although the 
composites were fractured. This indicated that the eight week implantation 
results were an underestimation of the real shear strength value. Nevertheless, 
these results confirmed our hypothesis that degradation of PLGA 
microparticles resulted in macroporosity of the CaP cement, followed by 
replacement of newly formed bone, and as a consequence in an increase of 
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mechanical properties. This effect was also described in other studies 
involving CaP cement.28,29  
To avoid complications with the sagittal sinus, the cranial defect size used in 
this study was not a critical size defect30,31, but, this was not a restriction for the 
aim of the study, i.e. the mechanical properties of CaP cement incorporated 
with PLGA microparticles. 
In this study, results from the push-out test assumed an equal load distribution 
at the bone-cement interface. However, test boundary conditions can 
significantly influence the load distribution.32 Nevertheless, these push-out 
results are still an approximation of the real bone-cement interface shear 
strength.  
Interestingly, large shear strength variations between samples from the same 
implantation period were observed. This variation can be explained by the 
differences in random distribution of the PLGA microparticles in the CaP 
cement. Accumulation of PLGA microparticles can result in relatively weak 
spots inside the composite, resulting in reduced push-out strength values. 
Large variations of the push-out test can also be due to differences between 
the rats, surgical techniques, and surface roughness or implant locations.33 
Some implants were press-fitted into the cranial defect, where others were 
less press-fitted. More bone formation was observed with the histological 
sections when close contact between implant and bone was detected, 
compared to implants with less contact between the implant and the cranial 
bone. Dhert et al. reported that mechanical test results can be influenced by 
implant fixation.32 In the future, this problem can be solved by applying 
CaP/PLGA composites as an injectable composite and not as pre-set discs. 
For this study, CaP/PLGA composites with weight ratios of 80% to 20% 
respectively were used. This composition was chosen based on previous 
research with similar CaP/PLGA cement composites. Previous in vitro research 
showed that PLGA microparticles started to degrade from week 6 and 
degradation was completed at week 12. Degradation of the PLGA 
microparticles resulted in reduction of the mechanical properties of the 
implants. This was also indicated in in vitro compression tests, in which the 
composites had an initial 30 MPa strength which was reduced to 4.3 MPa at 
12 weeks.34 Therefore, based on the in vitro compression tests and the results 
of the push-out test performed in the present study, we concluded that the 
CaP/PLGA composites are not suitable for load bearing purposes, since it was 
reported that the shear strength of compact bone ranges from 53.1 to 70 
MPa.35 Lowering the PLGA ratio in the composites could be considered to 
increase the mechanical properties of the implants, but this reduces the 
amount of bone ingrowth in the composites.  
Other factors, which influence the mechanical properties of the composites, 
are the total amount of porosity, pore size and pore structure.36 These factors 
should be appropriate to allow cell ingrowth and transport of nutrients and 
waste.37 In this study, the total porosity of the CaP/PLGA composites was 
approximately 67%, with microparticle sizes varying from 5 to 120 µm with an 
average diameter of 33 µm. These smaller microparticles have a less than 
optimal pore size for bone ingrowth as described by literature. Research by 
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others on the optimal pore size of porous ceramics varied between 50 and 
400 µm.36,38,39 Although, the average diameter is much smaller than the 
reported optimal size, there is still abundant ingrowth of bone in our 
specimens. This suggests that the optimal pore sizes may be much smaller for 
CaP cement than for materials with less favourable biological interactions.  
Further, porosity greatly influences the rate of degradation of the CaP 
cement. It was reported that degradation of macroporous CaP cement can 
reach up to 80% after ten weeks.10 However, crystallinity, density, pH in the 
implant region, animal model and implantation site also contribute to the rate 
of degradation.40 Therefore, complete degradation of the CaP cement varies 
between weeks to years depending on the physicochemical properties being 
used.41-44  
The increasing shear strength of the bone-cement interface over time was 
also confirmed by SEM examination, which showed a fracture plane at the 
bone-cement interface at two weeks, while the four and eight week 
specimens created a fracture plane into the CaP/PLGA composites, 
indicating an increased strength of the bone-cement interface. Histological 
evaluation confirmed that the two weeks implantation period resulted in 
minimal bone ingrowth. At four weeks of implantation, the peripheral PLGA 
microparticles were degraded and replaced by newly formed bone. Further, 
a small layer of bone was present at the cerebral side of the implants bridging 
the entire defect. Fibrous tissue was observed between the cranial bone and 
the CaP/PLGA composites, especially when no close contact was observed. 
After eight weeks of implantation, almost all PLGA microparticles were 
degraded and bone deposition was observed throughout the composites. 
SEM and histology revealed that bone formation started at the defect edges 
and cerebral side of the implant and proceeded into the macropores which 
were created by the degradated PLGA microparticles. This observation 
agrees with previously described bone deposition in porous ceramics which 
shows that a specific geometry and composition can have a beneficial 
effect on bone ingrowth.40,45  
 
Conclusions 
On basis of our results, we conclude that the shear strength of the bone-
cement interface increased over time due to bone ingrowth into the 
CaP/PLGA composites. Although the bone-cement contact could be 
optimized with an injectable CaP cement to enhance bone ingrowth, the 
mechanical properties of the composites after 8 weeks of implantation are 
still insufficient for load bearing purposes.  
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Introduction 
Autogenous bone is still considered to be the 'golden standard' for bone 
augmentation. However, due to the known limitations of autogenous bone 
grafting, such as donor site morbidity and limited supply, increasing efforts 
focus on the development of bone substitutes. In order to create a bone 
graft, which is comparable or superior to bone, allografts are combined with 
osteoinductive substances, such as growth factors. Transforming growth 
factor-β1 (TGF-β1) is a member of TGF-β superfamily, which regulates key 
aspects in bone metabolism.1 It affects osteoblast differentiation, matrix 
formation, and mineralization. Furthermore, it exerts its functions both during 
embryogenesis and in adult organisms, orchestrating complex phenomena 
such as inflammation and tissue repair.2 Studies have shown that TGF-β1 
supplied to a variety of biomaterials is able to enhance bone formation in 
vivo, depending on concentration and application method.3-5 Consequently, 
TGF-β1 is an appealing factor for use in clinical procedures for bone 
augmentation.   
As mentioned above, various materials have already been used for local 
delivery of TGF-β1, including calcium phosphate (CaP) ceramics.3-5 This 
material has been selected for bone replacement and augmentation due to 
its excellent bone behavior. The shortcomings of the prefabricated CaP 
ceramics, such as lack of shaping and difficult delivery to the defects, have 
been overcome by the development of injectable CaP cements.6 Injectable 
self-setting cement can fill macroscopic as well as microscopic bone defects. 
Cements of this kind may be resorbed, allowing gradual replacement by host 
bone.7 To promote degradation and tissue ingrowth injectable CaP cements 
have been combined with PLGA microparticles.8 Additionally, these 
degradable PLGA microparticles provide a method for delivery of bone 
formation promoting proteins, like TGF-β1. Such an injectable composite has 
been developed by our group and comprehensively studied in vitro and in 
vivo.8-10 However, the direct mode of application in a bone augmentation 
model has not been evaluated yet. 
In view of the above mentioned, the aim of this study was to examine the 
bone augmentation properties of injectable calcium phosphate 
cement/PLGA microparticle composites and to evaluate the additional 
effect of loading the composites with TGF-β1 in a rat model. 
 
Materials and Methods 
Materials 
The calcium phosphate cement Calcibon® (Biomet Merck, Darmstadt, 
Germany) was used in this study. The cement powder consisted of 62.5% α-
TCP (alpha tri-calcium phosphate), 61% α-TCP, 26% CaHPO4, 10% CaCO3 and 
3% PHA (precipitated hydroxyapatite). An aqueous solution of 1 % Na2HPO4 
was used as a liquid component with a liquid/powder ratio of 0.35 ml/g. Low-
molecular weight poly (D, L-lactic-co-glycolic acid) (PLGA) Purasorb® was 
provided by Purac, Gorinchem, The Netherlands. Human rh-TGF-β1 was 
supplied by R&D Systems, Abingdon, UK.  
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Preparation of PLGA microparticles  
PLGA microparticles were prepared using a water-in-oil-in-water (w/o/w)-
double emulsion solvent evaporation technique, as described previously by 
Ruhe et al.8 Briefly, 1.4 g of low molecular weight (LMW) PLGA was dissolved in 
2 ml of dichloromethane (DCM) inside a 50 ml PP tube. 500ml of ddH2O (or 
8.0/11.2 % BSA in ddH2O) was added while vortexing vigorously for 1 min, 
subsequently adding 6 ml of a 0.3% PVA solution. Vortexing was continued for 
another 1 min. The content of the 50 ml tube was transferred to a stirred 1000 
ml beaker and another 394 ml of 0.3% PVA was added slowly. This was directly 
followed by adding 400 ml of a 2% isopropylic alcohol (IPA) solution. The 
suspension was stirred for 1 hr. The spheres were allowed to settle for 15 min 
and the solution was decanted. The suspension left was centrifuged, and the 
clear solution at the top was decanted. 5 ml of ddH2O was added, the 
spheres were washed, centrifuged and the solution was aspirated. Finally the 
spheres were frozen, freeze-dried for 24 hr and stored under argon at -20°C.  
 
Adsorption of TGF-β1 on PLGA microparticles 
One μg of recombinant human TGF-β1 (rh-TGF-β1) was dissolved into 800 µl of 
0.1% acetic acid and added to 1.0 g of microparticles, after which the TGF-β1 
was freeze-dried onto the microparticles. The entrapment efficiency of the 
protein was determined by normalizing the amount actually entrapped with 
the amount added to the fabrication process. A calibration curve was 
generated through serial dilutions of rh-TGF-β1 solution to determine the 
quantity of rh-TGF-β1 (μg/ microsphere) using a gamma counter (Cobra II 
Autogamma, Packerd, Meridian, CT, USA).  
 
Preparation of CaP/PLGA composites 
CaP/PLGA composites were prepared by adding PLGA microparticles to the 
CaP cement powder in a weight ratio of 20% to 80% respectively. The cement 
powder was sterilized by gamma radiation with 25 kGy (Isotron B.V., Ede, the 
Netherlands) and the cement liquid was filter-sterilized (0.2 μm filter). Firstly, 
256 mg CaP cement powder provided with 64 mg PLGA microparticles was 
added to a 2 ml plastic syringe (Sherwood Medical Monojet 2 ml, 
Schwallbach, Germany). The mixture was shaken vigorously for 15 sec using a 
Silamat® mixing apparatus (Vivadent, Schaan, Liechtenstein). Subsequently, 
125 mg 1% Na2HPO4 was applied to the mixture, shaken again for 15 sec and 
then delivered by means of the syringe to the surgical site. CaP/PLGA 
composites provided with TGF-β1 were made by adding a fraction of TGF-β1 
adsorbed PLGA microparticles to a fraction of as-prepared PLGA 
microparticles, followed by the same procedure as described for the 
unloaded composites. The average amount of delivered material was 60 mg 
and the growth factor loaded composites contained 200 ng TGF-β1. 
 
Surgical procedure 
For the animal experiment, 24 healthy, skeletally mature male Wistar rats, with 
an average weight of 250 g, were used. National guidelines for care and use 
of laboratory animals were observed, and the animal ethical committee of 
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the Radboud University Nijmegen Medical Center approved the study 
protocol. In total, 48 composite implants were placed; each animal received 
2 implants from the same group on its parietal cranial bone for evaluation 
periods of 2, 4 and 8 weeks (n = 8 for each material and evaluation time).  
Anesthesia was induced with 4% Isoflurane by a non-rebreather mask and 
maintained with 2% Isoflurane, 0.4% N2O and 0.4% O2 during surgery. The 
animals were premedicated by an intramuscular injection of Fentanyl (2.7 
ml/kg) to reduce the operative pain, and a subcutaneous injection of 
Buprenorphine (150 µg/kg) was applied to reduce the postoperative pain.  
Before surgery, the rat cranium was shaved and swabbed by iodine. A medial 
sagittal incision extending from the nasofrontal area to the occipital 
protuberance was made and soft tissues were sharp dissected to visualize the 
cranial periosteum. Subsequently, the periosteum was undermined and 
reflected, exposing the parietal bones. A hollow trephine bur (ACE Dental 
Implant System, Brockton, MA, USA) with an outer diameter of 5 mm in a 
dental hand piece was used to mark the position of two augmentation sites 
on the parietal bone, aside from the sagittal sinus. The trephine bur did no 
penetrate into the whole thickness of the skull, but was stopped just in the 
upper part of the cortical plate next to the periosteum. Within the marked 
areas the cranial surface was scratched in order to remove part of the 
cortical bone and to get exposure of osteogenic cells. Afterwards, a silicon 
mold with a diameter of 5 mm, specifically designed for this purpose, was 
placed on the cranium and the CaP/PLGA composite was injected (Figure 1). 
In this way, implants in the form of discs were created, with a diameter of 5 
mm and a height of 2 mm. After setting of the composite, the mold was 
removed and the periosteum and overlying skin were closed in separate 
layers with 5-0 and 4-0 Vicryl resorbable sutures, respectively. 
 
Figure 1: Rat model for bone augmentation: A) 
defect, B) silicon mold, C) CaP/PLGA composite 
in mold, D) CaP/PLGA composite after setting 
and removal of the mold. 
 
 
 
 
 
 
 
 
 
Histological preparation 
The animals were sacrificed 2, 4, and 8 weeks after surgery using an overdose 
of carbon dioxide. The skin was dissected and the defect sites were removed 
along with the surrounding bone and soft tissues, and fixed in 10% neutral 
formalin for one week. Half of the specimens (n = 4 per material and 
evaluation time) were dehydrated in gradual series of alcohol and 
embedded in polymethylmethacrylate (PMMA). Before the embedding 
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procedure, samples were cut exactly through the middle of the implants to 
secure that the microtome sections were made in the area of interest and the 
same region was analyzed for each sample.After polymerization, sections 
were prepared using a modified diamond-blade sawing microtome 
technique (Leica Microsystems GmbH, Wetzlar, Germany). Obtained sections 
were approximately 10 µm thick and stained with methylene blue and basic 
fuchsin. The remaining specimens (n = 4 per material and implantation time) 
were decalcified for 2 weeks in Formical-2000 (Immunodiagnostika & Biotech 
GmbH, Berlin, Germany) and then embedded in Paraplast paraffin (Klinipath 
B.V., Duiven, the Netherlands). Sagittal microtome sections were made, 5 µm 
in thickness, which were stained with hematoxylin-eosin and 
immunohistochemically using an antibody against CD68 (Macrosialin11 to 
detect inflammatory cells including monocytes, macrophages, and 
neutrophils. Again, before the embedding procedure, samples were cut 
exactly through the middle of the implants.  
The light microscopical evaluation of all sections was done using an optical 
microscope (Leica BW, Rijswijk, the Netherlands), and consisted of a 
complete morphological description of the tissue response to different 
implants as well as of histomorphometrical analysis.  
 
Histomorphometry 
For the histomorphometrical analysis, a Leica Qwin Proimage analysis system 
(Leica BV, Rijswijk, the Netherlands) was used. Sections were digitized at low 
magnification (2.5 x) and measurements were done on three sections per 
cranial specimen. All PMMA sections were used for evaluation of bone 
response and all paraffin sections for assessment of inflammatory reaction. 
To quantify the amount of bone augmentation, newly formed bone, as 
stained and discerned by its woven structure and location, was marked 
manually and its area was measured. Afterwards, this ROI was subtracted 
from the whole area of the implant. From these two data, the amount of 
bone formation (%) was calculated.  
 In order to measure the contact length between the implants and the bone, 
lines were drawn manually at the direct interface between the composites 
and newly formed bone. The sum of these intersections was calculated and 
interpreted as contact bone/composite length.  
Further, the intensity of the inflammatory response around the implants was 
quantified. For this purpose pictures with higher magnification (i.e 10x) were 
used. The presence of macrophages was detected with anti-CD68 staining 
and subsequently digitized by a computer programme in the region of 
interest (implant + surrounding tissue; ROI). The areas with positive anti-CD68 
staining were given as a percentage (%) of the total ROI.  
 
Statistical analysis 
For the statistical analyses, GraphPad InStat program (GraphPad Software, 
San Diego, CA, USA) was used. One-way Analysis of Variance (ANOVA) was 
performed on the data obtained from the histomorphometric analyses. 
ANOVA assumes that the data are sampled from populations with identical 
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standard deviations. This assumption was tested using the method of Bartlett. 
Further, ANOVA assumes that the data are sampled from populations that 
follow Gaussian distributions. This assumption was tested using the method of 
Kolmogorov and Smirnov. In addition, a Tukey-Kramer Multiple Comparisons 
Test was done. Differences were considered to be significant when p < 0.05. 
 
Results 
General observations 
The injection of the composite into the silicon mold placed on the scratched 
cranial surface went without complications. The setting time of both loaded 
and unloaded composites was about 10 min. Setting and handling properties 
of the composites were influenced by the presence of blood. When the 
composite was injected on dry, good isolated cranial surfaces the setting 
time was shorter, the composite was easily shaped, and after removal of the 
mold the implant was secured more stable. Mixing with blood affected the 
handling properties of the composites and made them more fragile. In 
addition, the composites loaded with TGF-β1 appeared to be more fragile 
after setting than the unloaded composites, as indicated by easy cracking. 
During the implantation periods all animals remained in good health. At 
sacrifice, macroscopic signs of inflammation and adverse reaction were 
apparent around loaded as well as unloaded implants predominantly after 2 
and 4 weeks. After 8 weeks, the signs of inflammation disappeared. Upon 
retrieval, all implants in both groups were in situ and surrounded by a fibrous 
capsule. The capsule thickness differed between different time points with a 
tendency of reduction for the later periods. No differences between the 
loaded and unloaded composites were observed.  
 
Figure 2: Light micrographs of 
PMMA embedded specimens 
showing bone augmentation 
at different time points (2.5x 
magnification).            
 
 
 
 
 
 
 
 
Descriptive histology 
Histological examination of PMMA embedded samples revealed new bone 
formation in both groups at all time points. Newly formed bone was more 
abundant at 4 and 8 weeks in comparison to its amount at 2 weeks (Figure 2). 
Bone formation was observed at the defect margins and along the lower part 
of the cement at the side of the cranium. No bone formation was seen from 
the periosteum side on the top of the implants, as well as throughout the 
implant. At higher magnification, newly formed bone revealed thin 
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trabeculae and large marrow spaces filled with fat tissue and 
haematopoietic cells. In addition, a direct contact between the composites 
and newly formed bone, without any fibrous tissue interface, was apparent in 
both experimental and control groups (Figure 3). 
 
 
Figure 3: Histological section of PMMA embedded 
specimen (10x magnification). Guided bone 
formation is visible with direct contact composite - 
newly formed bone without any fibrous tissue 
interface. Dash line in yellow indicates the transition 
between the newly formed bone and the old bone. 
OB - old bone, NB - newly formed bone, C – 
composite. 
 
 
 
 
 
Furthermore, implants managed to stay in place during all investigation 
periods. However, the integrity of the composite structure appeared to be 
affected. Fractures, as observed inside the implants, were filled with fibrous 
tissue and inflammatory cells. Signs of inflammation were at best visible in the 
paraffin sections stained for CD68. The inflammatory infiltrate, consisting of 
macrophages and lymphocytes, surrounded the implants and penetrated 
into the composite structure. In the course of time a substantial decrease in 
the inflammatory response was observed in both groups (Figure 4). Together 
with the decrease in inflammation, a consolidation of the implant fragments 
and their incorporation in the bone tissue was noticed. 
Paraffin sections stained with hematoxylin-eosin did not provide any 
additional information to the PMMA sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Light micrographs of paraffin sections stained for CD68 showing the inflammatory 
response at different time points (2.5x magnification). 
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Histomorphometry 
The amount of newly formed bone was almost the same for both 
experimental and control groups after 2 and 4 weeks. At 8 weeks, there was 
more bone formation in the group of TGF-β1 loaded implants (18.5% ± 3) than 
in the group of the unloaded ones (7.2% ± 5), which was statistically significant 
(p<0.05; Figure 5). 
The contact length between the composites and newly formed bone 
increased in time. At 2 weeks TGF-β1 loaded samples showed significantly 
better bone contact than unloaded controls (19 mm ± 7 vs. 2.7 mm ± 4 and 
p<0.05). After 4 and 8 weeks, no difference in the contact length was 
observed between the groups (Figure 6). 
The amount of inflammation after 2 weeks was substantial for both groups. 
However, after 4 weeks it decreased to 9.0% ± 2 for the TGF-β1 loaded 
implants and to 13.3% ± 2 for the controls. This difference between the groups 
appeared to be statistically significant (p<0.01). At 8 weeks a minor 
inflammation was observed in both groups (Figure 7). 
 
 
Figure 5: Histomorphometric measurements 
of bone formation in percentage for all 
evaluation periods. Asterisk (*) indicates 
statistically significant difference (p<0.05). 
 
 
 
 
 
 
Figure 6: Histomorphometric measurements 
of composite/bone contact length for all 
evaluation periods. Asterisk (*) indicates 
statistically significant difference (p<0.05). 
 
 
 
 
 
 
Figure 7: Histomorphometric measurements 
of the amount of inflammation in 
percentage for all evaluation periods. 
Asterisk (**) indicates statistically significant 
difference (p<0.01). 
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Discussion 
The present study demonstrates that the used injectable CaP/PLGA 
composite stimulated bone augmentation in a rat model. Moreover, the 
addition of TGF-β1 to the composite significantly enhanced new bone 
formation at 8 weeks when compared to the control (i.e. unloaded 
CaP/PLGA composite). These findings corroborate the results of Vuola et al.12 
In their rat cranial model TGF-β1 loaded coral based implants enhanced 
bone regeneration, and the amount of newly formed bone was also not 
significantly higher compared to the controls until the 8th week. The authors 
suggested that the influence of TGF-β1 on bone formation lasted several 
weeks and diminished with age. In the study of Vuola et al.12 6-8 months old 
rats, weighing 550-560 g, were used. In our study the experimental animals 
were younger, yet skeletally mature, and with a weight of approximately 250 
g. Further, the concentration of TGF-β1 incorporated in our composites (200 
ng) was much lower than that used in the study of Vuola et al. (1, 2 and 25 
µg). 
The effect of TGF-β1 on bone formation is known to be dose dependent, 
however it has to do more with an optimal than with a maximal dose.13 For 
example, Blom et al.14 reported enhanced bone formation for the same 
implantation period with very low concentrations of TGF-β1 (10 ng and 20 ng) 
incorporated in a similar type of CaP cement. In the current experiment 
enhanced bone formation was observed also with a lower TGF-β1 dose than 
applied in similar studies.3,15 Therefore, it can be suggested that the amount of 
TGF-β1 needed to exert an effect may depend on the type of carrier used.  
Delivery systems are of great importance when growth factors are utilized to 
enhance bone-healing process.16 In previous studies8,9 it was demonstrated 
that: (a) CaP/PLGA composite is a suitable carrier for growth factors, and (b) 
the method of  loading growth factors on the scaffold (freeze-drying on top 
of the PLGA microparticles) does not affect their osteoinductive properties. 
However, the high protein binding affinity of CaP cement must be taken into 
account. Therefore, it can be hypothesized that after release from the PLGA 
microparticles, TGF-β1 may have bound to the CaP cement resulting in a 
delayed release from the composite. This might explain why no increase in 
bone formation was seen after 4 weeks for TGF-β1 loaded materials 
compared to the controls. At the moment, it is still unclear whether the TGF-β1 
as bound to the CaP cement has maintained its osteoinductive properties. 
We have to notice that this has to be an issue of investigation. 
It has also to be emphasized that the effect of TGF-β1 on bone formation 
differs among species. In general, studies using rodents and primates as 
experimental models do not report so favourable outcomes concerning the 
osteoinductive ability of TGF-β1 compared to studies using dogs.17
In the current study the release kinetics of the TGF-β1 from the CaP/PLGA 
composite was not examined. On the other hand, similar designed CaP/PLGA 
composites were recently used in another study for the delivery of enmal 
matrix derivate (EMD).18 An in vitro assay revealed that after 4 weeks only 60% 
of EMD was released from these scaffolds, and this sustained release 
continued as observed during extended follow-up periods. In view of this, it 
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can be speculated that such a release pattern is too slow for TGF-β1 to 
support early bone development. Therefore, the TGF-β1 induced bone 
formation after 4 weeks was enhanced but not statistically significant 
compared to the control. Nevertheless, it must be taken into account that 
EMD and TGF-β1 are completely different proteins. Additionally, the EMD 
release profile was determined in vitro, which is known to differ from the in 
vivo situation. In this regard, in vitro and in vivo TGF-β1 release profiles from 
CaP/PLGA composites are necessary to prove the above-mentioned 
hypothesis.  
Another reason for lack of significant difference in the amount of newly 
formed bone between the groups at 2 and 4 weeks could be the material 
used as a control. The CaP/PLGA composite material has already 
demonstrated excellent bone regenerative capacity in previous rat studies.18 
It is a fast-setting type of cement, which still provides sufficient time for 
molding and contouring in order to achieve precise adjustment to the defect 
or augmentation site.19,20 The initial material/bone (material/implant) contact 
is of utmost importance for integration of the filler material and early onset of 
remodeling. In case of discontinuity in the material/bone (material/implant) 
interface, fibrous tissue ingrowth between the filler and the bone/implant will 
delay bone formation and might result in failure. To estimate material/bone 
interface, bone contact measurements were performed. In the current study, 
the bone contact length for the CaP/PLGA composite increased from 2.76 to 
39.63 mm during 8 weeks of implantation. Moreover, TGF-β1 loading resulted 
in an additional increase of the initial bone contact, since this material 
showed significantly higher values of contact length at 2 weeks in comparison 
with the unloaded material. 
Concerning the material application method in this study, direct injection of 
the CaP/PLGA composite without fixation was chosen due to the close 
resemblance of this mode of application to the final clinical approach. 
Nevertheless, it should be taken into account that lack of rigid fixation of the 
implants to the skull can have influenced bone formation. Rigid fixation is 
known to decrease movement and shear forces on the graft, thereby 
improving revascularization and resulting in earlier bone apposition and 
improved osteoconduction.21-23
Finally, at two weeks of implantation, a serious inflammatory response to the 
CaP/PLGA material was observed. In view of this, it has to be noticed that the 
mechanical properties of the CaP/PLGA composite are limited. As a 
consequence, tight closure of the periosteum and subcutaneous tissue over 
the implants can have caused a high pressure resulting in the occurrence of 
fractures in the cement material. These fractures can be associated with the 
appearance of small CaP particles. Orthopedic implant studies have already 
highlighted that CaP particles can induce an inflammatory response24-26 or 
can alter osteoblast functions if their size is smaller than 10 µm.27 As a result, 
bone formation will be delayed until the particles are completely resorbed. A 
study performed on calvarial rat osteoblasts confirmed the adverse effect of 
small CaP particles (<10 µm) on bone formation.24 In addition to the presence 
of small CaP particles, the cement setting and transformation can have 
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contributed to the observed inflammatory response. These processes involve 
phase transformation of the ceramic with an associated substantial decrease 
in pH (pH ~5.5).28 The increased acidity around the implant can be 
responsible for the appearance of inflammatory cells. All these observations 
are in agreement with the study of Huse et al.29, who also found an extensive 
inflammatory infiltrate into the pores of similar injectable CaP cement loaded 
with TGF-β1 in an onlay rat model.    
 
Conclusion 
In summary, the injectable CaP/PLGA composites stimulated bone 
augmentation in a rat model. The addition of TGF-β1 to the composite 
significantly increased bone contact at 2 weeks and enhanced new bone 
formation at 8 weeks. For clinical application, mechanical properties of the 
injectable composite after setting have to be improved. 
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Introduction 
Porous calcium phosphate (CaP) cements are promising scaffold materials in 
bone tissue engineering approaches. These CaP cements consist of a mixture 
of powder and liquid, which hardens in situ as a result of the entanglement of 
newly formed crystals at body temperature. Although injectable CaP cement 
shows excellent biocompatibility and osteoconductivity, resorption in vivo is 
slow.1 The intrinsic nanoporosity of the CaP cement only allows transport of 
nutrients and waste and does not allow tissue ingrowth.2-4 Therefore, methods 
have been developed to accelerate resorption and tissue ingrowth by 
creating microporosity in the CaP cement. One method involves the 
incorporation of polymeric microparticles, such as poly (D,L-lactic-co-glycolic 
acid) (PLGA) microparticles inside the CaP cement.3,5-8 Previous studies 
showed that degradation of PLGA microparticles takes 6 to 12 weeks.5 This 
slow degradation is likely to prevent rapid cell penetration into the implant, 
which would delay intra-implant bone formation. Even more ideally, a 
scaffold that contains microparticles with variation in degradation rates is 
preferred, hence allowing the creation of bone substitute materials, which 
combine rapid cell penetration (after rapid microparticle degradation) with a 
sustained release of appropriate growth factors (from slow degrading 
microparticles). 
For microparticle preparation, the use of a polymer from natural sources, such 
as gelatin, is appealing as a biodegradable, biocompatible and non-toxic 
substitute for synthetic degradable polymers.9,10 During the fabrication 
process of commercially available gelatin either a positively-charged alkaline 
gelatin (type A), or a negatively-charged acidic gelatin (type B) at 
physiological pH can be obtained.11 The application of these types of 
gelatine for microparticle preparation further allows a certain degree of 
control over thermal and mechanical stability of the microparticles under 
physiological conditions and the related degradation rate by crosslinking with 
glutaraldehyde.12,13 After degradation of the gelatin microparticles by 
members of the matrix metalloprotease (MMP) family (including gelatinases 
and collagenases)14 microporosity is created in the CaP cement. 
In view of the above mentioned, this study focused on the degradation 
properties and the subsequent effect on bone formation of gelatin 
microparticles incorporated in CaP cement in a critical-sized cranial defect in 
rats. CaP/gelatin composites were prepared using either alkaline or acidic 
gelatin microparticles. Degradation properties were obtained by measuring 
gamma emission of remaining radioiodinated gelatin microparticles in the 
CaP cement implants after implantation periods of two, four, and eight 
weeks. Additionally, histological and histomorphometrical analyses were 
performed to evaluate general tissue responses and the amount of new bone 
formation. 
 
Materials and Methods 
Gelatin microparticles 
The preparation of gelatin microparticles was based on procedures 
described previously by Holland et al.15 Briefly, a gelatin solution was 
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prepared by dissolving 2.5 gram type A (pI = 7.0–9.0) or type B (pI= 4.7-5.2) 
gelatin (Sigma, St.Louis, MO, USA) in 22.5 ml MilliQ at 37°C for 1 hour. Then, this 
solution was added drop by drop to 125 ml chilled (4°C) olive oil (Acros 
Organics, Geel, Belgium) under continuous stirring at 500 rpm. After 30 min, 50 
ml chilled acetone (4°C; HPLC grade, Labscan Ltd., Dublin, Ireland) together 
with 1 ml 25 w/v% glutaraldehyde (Merck, Darmstadt, Germany) was added 
to the emulsion. After stirring for an additional 30 min, the microparticles were 
collected by filtration and washed with chilled acetone (4°C). Finally, the 
microparticles were frozen and lyophilized. Microparticle size distribution was 
assessed by morphometrical analysis using a light microscope (Leica 
Microsystems AG, Wetzlar, Germany) and computer based image analysis 
techniques (Leica® Qwin Pro-image analysis system, Wetzlar, Germany). 
 
Radioiodization of gelatin microparticles 
Type A and B gelatin microparticles were labeled with Iodine125 (Amersham 
Biosciences, Buckinghamshire, UK) using Iodogen, a solid-phase oxidizing 
agent that catalyzes the reaction to achieve a chemical link between 
radiolabel and a protein.16 Briefly, 100 µl of gelatin microparticles suspension in 
PBS (100 mg/ml) was reacted with 100 µCi Iodine125 in a reaction vial coated 
with 50 µg iodogen during 10 min. at room temperature in 50 mM phosphate 
buffer (pH 7.4). The suspension was then centrifuged in an eppendorf 
microcentrifuge (5000 rpm, 5 min.) and the pellet was washed four times with 
1 ml PBS. The specific activity of the acidic and alkaline gelatin microparticles 
was 2 µCi/µg. Hot/cold suspensions of gelatin microparticles were prepared in 
ratio of 1:4 for the in vivo study. 
 
CaP/gelatin composites 
The CaP cement Calcibon® (Merck biomaterial GmbH, Darmstadt, Germany) 
was used for the preparation of the CaP/gelatin composites. The chemical 
composition of this cement is 61% α-TCP, 26% CaHPO4, 10% CaCO3 and 3% 
PHA (α-TCP is alpha tri-calcium phosphate, PHA is precipitated 
hydroxyapatite). Type A or B gelatin microparticles (50 mg) were pre-swollen 
in 300 µl water (complete absorption) and mixed for 15 sec in a 2 ml syringe 
(Sherwood medical monoject) with closed tip using a mixing apparatus 
(Silamat, Vivadent, Schaan, Liechtenstein). CaP cement powder (950 mg) 
was added afterwards in the 2 ml syringe. The final injectable composite was 
obtained by adding 350 μl of Na2HPO4 (1 wt%) to 1000 mg of this CaP/gelatin 
mixture and mixing it for 15 sec with the mixing apparatus. Subsequently, the 
CaP/gelatin composite was immediately injected into teflon molds (8.0 mm in 
diameter and 2.4 mm in height) to ensure a standardized shape of the 
composite discs. The composite discs were removed of these molds after 
cement setting at room temperature for one day. The total porosity of the 
different CaP/gelatin composites was determined by correlating the weight 
of CaP discs with the weight of CaP/gelatin discs after placement of the 
samples in a furnace at 650°C for 2 hours to remove the gelatin 
microparticles.5 
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Surgery 
Forty-eight Wistar male rats (weight ±250g) were used, which individually 
received one CaP/gelatin composite disc implanted into a circular critical 
sized cranial defect of 8 mm.17 Half of the rats received discs with type A 
gelatin microparticles (18 without, 6 with radiolabel), and the other half 
received discs incorporated with type B gelatin microparticles (18 without, 6 
with radiolabel), which were implanted for two, four, and eight weeks. The 
animal experiment was approved by the Animal Ethical Committee of the 
Radboud University Nijmegen Medical Center and national guidelines for the 
care and use of laboratory animals were observed. 
Surgery was performed under general inhalation anesthesia, induced by 4% 
isoflurane and maintained with 2.5% isoflurane by a non-rebreather mask. The 
rats were monitored with an oxy-pulse meter during surgery. To minimize 
postoperative pain, Fentanyl® (3 ml/kg i.p.) was administered preoperatively 
and buprenorfine (Temgesic®) (0.05 mg/kg s.c.) postoperatively.  
After anesthesia the rats were immobilized on their abdomen and the skull 
was washed and disinfected with iodine. A longitudinal incision was made 
down to the periosteum from the nasal bone to the occipital protuberance, 
and soft tissues were sharp-dissected to visualize the cranial periosteum. 
Subsequently, a midline incision was made in the periosteum and the 
periosteum was undermined and lifted off the parietal skull. To minimize pain, 
lidocaine was administered onto the periosteum before incision. To create a 
central full thickness bone defect in the parietal cranium, a hollow trephine 
drill (ACE dental implant systems, Portugal) with an outer diameter of 8.0 mm 
in a dental handpiece was used. The bone defect was carefully drilled under 
continuous cooling with physiologic saline, without damaging of the 
underlying dura. Then, the created bone segment was carefully removed, 
without damaging the underlying sagittal sinus. Following insertion of a 
CaP/gelatin composite disc, the periosteum was closed using resorbable 
Vicryl® 5-0 suture material. Subsequently, the skin was closed using resorbable 
Vicryl® 4-0 sutures. To minimize post-operative discomfort, treatment with 
Temgesic® was continued for two days post-operatively. Two animals were 
housed in each cage. The proper intake of fluids and food was monitored in 
the first five days post-operatively. Also, the animals were observed for signs of 
pain, infection and proper activity. The rats were euthanized two, four or eight 
weeks after surgery by an overdose of CO2/O2 suffocation. 
 
Degradation assay 
Prior to surgery, CaP discs incorporated with either type A or B radioiodinated 
gelatin microparticles (both n=6) were measured in a gamma well-type 
counter (Wizard, Pharmacia, Uppsala, Sweden). These samples were destined 
for implantation in a critical-sized cranial defect as mentioned before. After 
both four and eight weeks of implantation, six rats (three with gelatin A and 
three with gelatin B) with the radioiodinated implants were euthanized by 
CO2 suffocation. The implants with their surrounding tissue were retrieved and 
measured in a gamma counter ex vivo. Standards were counted 
simultaneously to correct for radioactive decay. The remaining activity in the 
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discs was expressed as percentage of the initial activity and is a criterion for 
the remaining amount of gelatin left in the composites. 
 
Scanning electron microscopy (SEM) 
To obtain information about the morphological appearance of the 
composites, the twelve implants of the degradation assay were fixated in 10% 
formalin solution and dehydrated in a graded series of ethanol. After 
longitudinal breakage of the implants, samples were sputter-coated with gold 
and examined with SEM (Jeol 6310 scanning electron microscope, Boston, 
MA, USA). SEM was performed at the Microscopic Imaging Center (MIC) of 
the Nijmegen Center for Molecular Life Sciences (NCMLS), the Netherlands. 
 
Histological and histomorphometrical evaluation 
After euthanizing the rats, the implants with their surrounding tissue were 
retrieved and prepared for histological evaluation. The samples were fixated 
in 10% formalin solution (pH=7.4), dehydrated in a graded series of ethanol 
and embedded in methylmethacrylate. Following polymerization, three 10 µm 
thick sections were prepared per implant using a sawing microtome 
technique.8 The sections were stained with methylene blue and basic fuchsin 
and investigated with a light microscope. For the histomorphometrical 
analysis all sections per implant were evaluated using a computer based 
image analysis technique (Leica® Qwin Pro-image analysis system, Wetzlar, 
Germany). The quantitative evaluation of newly formed bone was calculated 
by determining a region of interest (ROI) which was set between the surface 
area of both ends of the originally created critical-sized defect. Within this ROI 
new bone formation was distinguished from pre-existing bone and composite 
through structure and color differences. New bone formation was expressed 
in mm2, using standardization of the 2-dimensional region of interest. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using analyses of variance 
(ANOVA) combined with a Tukey’s test to correct for multiple comparison. 
Significance was set at p<0.05. 
 
Results 
Implant characterization 
The generation of type A gelatin microparticles resulted in a diameter 
distribution of 1 to 161 µm with an average size of 37.4 ± 31.1 µm. The diameter 
distribution of the type B gelatin microparticles varied between 1 to 66 µm 
with an average size of 20.7 ± 14.6 µm. The porosity of the implants was 48.7 ± 
0.1 % for the implants containing type A gelatin microparticles, and 45.0 ± 1.3 
% for the implants containing type B gelatin microparticles (Table 1).   
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Table 1: Implant 
macroporosity and gelatin 
microparticle sizes. 
 
 
 
 
In vivo experiment 
General observations 
All forty-eight Wistar male rats remained in good health and did not show any 
wound complications. At retrieval, the cranial implants were all covered by 
periosteum and implants remained intact. No inflammatory signs or adverse 
tissue reactions were observed. 
 
SEM examination 
SEM examination of CaP/gelatin composites after implantation (Figure 1) 
showed a homogeneous distribution of type A and B gelatin microparticles 
throughout the implants. The gelatin type A composites contained larger 
microparticles compared to gelatin type B composites. The four and eight 
week implantation period showed a similar composite morphology. 
Generally, gelatin microparticle degradation appeared to start at the implant 
periphery, as microparticles in the core of the implant appeared to be intact. 
However, surface erosion of microparticles was observed within all samples, 
indicated by the deformation of microparticle structure (Figure 1E). No 
apparent differences were observed between implants containing either 
type A or B gelatin. 
 
 
Figure 1: SEM examination of type A 
(A&B) and B (C,D&E) gelatin 
microparticles incorporated in CaP 
cement implants after eight weeks of 
implantation. Surface erosion of 
microparticles is observed, indicated by 
the deformation of the microparticle 
structure (arrowheads).   
 
 
 
 
 
 
 
 
 
 
 
 
84 
Degradation study 
The implants with their surrounding tissue were retrieved and the retained 
activity was determined using a gamma counter ex vivo. The remaining 
activity of the radioiodinated type A gelatin microparticles was 14.3 ± 0.5 % 
and 11.3 ± 0.9 % after four and eight weeks of implantation, respectively. 
Radioiodinated type B gelatin microparticles showed a remaining activity of 
18.1 ± 1.4 % and 19.6 ± 4.4 % after four and eight weeks of implantation, 
respectively. Statistical analysis showed significantly lower remaining activity 
for type A compared to type B gelatin microparticles after both four and 
eight weeks of implantation (Figure 2).   
 
Figure 2: Remaining Iodine125 
activity (in %) of the type A and B 
gelatin microparticles incorporated 
in CaP cement implants. Significant 
differences (p<0.05) are indicated 
with an asterisk (*). 
 
 
 
 
 
 
 
 
Histological and histomorphometrical evaluation 
Light microscopic analysis of the histological sections of the implants showed 
similar results for implants containing either type A or B gelatin microparticles. 
The two week implantation period (Figures 3A&D) resulted in minimal bone 
formation from the cranial bone towards the implant. After four weeks of 
implantation (Figures 3B & E), a thin layer of newly formed bone was present 
from the cranial bone towards the implant periphery. Occasionally, limited 
bone formation at the cerebral side of the implant was observed. After eight 
weeks of implantation (Figures 3C & F) a layer of newly formed bone was 
present from the cranial bone towards the implant periphery. Bone ingrowth 
into the implant was predominantly observed at sites of gelatin microparticles 
degradation at the implant periphery (Figure 4C). Also, bone formation at the 
cerebral side of the implants was observed, although no bridging of the entire 
defect was observed (Figure 4B). At all implantation periods, fibrous tissue 
between implants and cranial bone was observed, especially in case there 
was no close contact between implant and bone (Figure 4A). No bone or 
fibrous tissue was observed in the center of the implants after any of the 
implantation periods. 
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Figure 3: Histological sections of CaP cement implants containing type A gelatin 
microparticles after two (A), four (B) and eight (C) weeks of implantation as well as implants 
containing type B gelatin microparticles after two (D), four (E) and eight (F) weeks of 
implantation. 
   
 
Figure 4: Magnification of histological sections of CaP cement implants containing type A 
gelatin microparticles after two (A) and eight (B & C) weeks of implantation. (B = cranial 
bone, F = fibrous tissue, N= newly formed bone) 
 
 
Histomorphometrical evaluation showed no significant differences between 
composites with either type A or B gelatin microparticles regarding bone 
formation after any of the implantation periods (Figure 5). Generally, only 
limited amounts of newly formed bone were found in both type A and B 
gelatin microparticle composites. Implants containing type A microparticles 
showed 0.03 ± 0.04 mm2 new bone after two weeks, 0.37 ± 0.23 mm2 after four 
weeks, and finally 0.60 ± 0.50 mm2 after eight weeks of implantation. The 
samples containing type B gelatin microparticles showed 0.07 ± 0.07 mm2 new 
bone after two weeks, 0.23 ± 0.37 mm2 after four weeks, and finally 0.58 ± 0.14 
mm2 after eight weeks of implantation. 
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Figure 5: New bone formation (in 
mm2) of CaP cement implants 
containing type A or B gelatin 
microparticles after two, four, and 
eight weeks of implantation. 
 
 
 
 
 
 
 
 
Discussion 
In this study, the degradation properties and the subsequent effect on bone 
formation of gelatin microparticles incorporated in CaP cement in a critical-
sized cranial defect in rats were examined. More specifically, the use of a 
natural polymeric material for the generation of microparticles was 
evaluated, since such a material is hypothesized to degrade more rapidly as 
compared to synthetic polymeric materials. The natural polymer gelatin was 
used in either an alkaline or an acidic form to reveal potential differences in 
degradation of resulting microparticles. 
Implant characterization demonstrated that the macroporosity of the 
composites was 48.7 ± 0.1 % for composites containing type A gelatin 
microparticles, and 45.0 ± 1.3 % for the composites containing type B 
microparticles. In view of previous studies with PLGA microparticles8 this 
porosity should be high enough to obtain an interconnective network after 
degradation. However, porosity is not the only important factor in 
interconnectivity. Previous research showed that interconnection was not 
solely relying on high porosity, but merely on microparticle size.8 Nonetheless, 
no fibrous tissue or bone formation was observed in this study throughout the 
implants, which is the parameter to indicate in vivo interconnectivity. 
Although no CaP precipitates were observed in this study, Habraken et al.17 
showed that CaP can precipitate inside and onto the gelatin microparticles. 
Consequently, after degradation of two adjacent microparticles a shell of 
hydroxyapatite was created, instead of an interconnection. This could explain 
insufficiency of the used 5 wt% gelatin microparticles in this study to obtain 
interconnected pores. Therefore, increasing the microparticle weight 
percentage is likely to solve this problem at least partially, although 
precipitation of CaP still can occur and problems with setting time of the 
composites could emerge if the weight percentage is above a certain 
threshold.17 
SEM examination showed that gelatin microparticles were degraded at the 
implant periphery, whereas in the core of the implant, microparticles 
appeared to be intact. Prior to microparticle degradation, our implants only 
possessed an intrinsic nanoporosity without an interconnected microporous 
87 
network. Therefore, fluid flow in the center of the implants was likely limited 
compared to that at the implant periphery. As a result, binding and/or 
activation of proteolytic enzymes can be different at these sites, thus limiting 
gelatin degradation in the center of the implants.18 
The degradation study showed that the remaining radioactivity of the 
composites containing type A gelatin microparticles was lower than the 
composites containing type B gelatin microparticles. The difference between 
type A and B gelatin microparticles degradation was significant. This could be 
explained by a higher porosity and larger microparticle size of the type A 
gelatin, which results in faster degradation of the microparticles.17 
Furthermore, the difference in charge and acidity could also account for the 
differences in degradation. Remarkably, the difference between the 
remaining radioactivity after four and eight weeks implantation was minimal. 
Apparently, radioiodinated gelatin was still present in the core of the 
composites. This could be explained by the binding properties of gelatin to 
CaP19 and the high binding affinity of CaP cement for proteins20,21, resulting in 
a strong bond between the CaP cement and the gelatin.  
Unfortunately, long-term measurements with the same composites in vivo 
could not be performed, due to the low energetic emission of the Iodine125 
label. Other radioactive isotopes (Iodine131 and Indium111) were considered 
for gelatin microparticle labeling, but were unsuitable to use for gamma 
camera measurements due to their short half-lives of 8 and 3 days, 
respectively. Therefore, samples could only be measured in a gamma 
counter ex vivo before implantation and after sacrificing the animals. 
Furthermore, for the chosen method to study gelatin microparticle 
degradation, the assumption was made that the chemical linkage of the 
radiolabel resulted in homogeneously radiolabeled microparticles rather than 
radiolabeling according to a gradient. This assumption is plausible, since the 
microparticles are hollow and consist of a thin shell of gelatin.18 However, the 
authors recognize the limitations of this method. Therefore, it is likely that 
radioactivity measurements represent an indirect method to determine 
gelatin microparticle degradation. It needs to be emphasized, however, that 
the measured radioactivity includes not only the remaining intact 
radioiodinated gelatin microparticles, but also remaining partially degraded 
gelatin microparticles. Therefore, the measured radioactivity does not 
automatically indicate that the microparticles are completely degraded. 
Histological evaluation showed that fibrous tissue was observed between 
composite and cranial bone, especially in case there was no close contact 
between implant and bone. No bone or fibrous tissue was observed in the 
center of the composites after any of the implantation periods, probably due 
to the lack of interconnectivity. Therefore, bone ingrowth was only observed 
at the periphery of the composites after degradation of gelatin 
microparticles. 
Histomorphometrical evaluation showed that between implants containing 
type A and B gelatin microparticles, no significant differences in bone 
formation occurred during all implantation periods. This could be explained 
by the excellent osteoconductivity of the CaP cement.1,22,23 However, the 
88 
amount of newly formed bone in this study was limited as compared to 
previous research with CaP cement implants.4,7,23 Factors including surgical 
technique, differences between animals or implant locations are known to 
effect bone formation.24 
 
Conclusions 
In conclusion, this study demonstrates that gelatin type influences the 
degradation of gelatin microparticles incorporated in CaP cements. 
However, this difference in degradation and the concomitant subsequent 
macroporosity did not induce differences in the biological response.  
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Introduction 
Calcium phosphate (CaP) ceramics are widely used as bone substitutes in 
reconstructive orthopedic and oral surgery because of their beneficial effects 
on bone healing. These ceramics can be applied as granules or 
prefabricated porous blocks, but they can also be formulated as an 
injectable CaP paste that can be shaped according to the required 
dimensions.1-5 These so-called CaP cements are highly compatible with soft 
and hard tissues after setting in situ.6 In view of tissue reconstruction, CaP 
cements are supposed to be subject of biological degradation and 
concomitant replacement by bone tissue. However, the degradation of CaP 
cements is known to be slow7, which is likely due to the limited extent of 
porosity. CaP cements contain only an intrinsic nanoporosity which allows 
transport of nutrients and waste through the material, but the dimensions of 
this nanoporosity are insufficient to obtain tissue ingrowth.6 As a 
consequence, attempts have been made to increase the porosity of the 
material to allow tissue ingrowth and to accelerate degradation.8,9 For the 
additional creation of microporosity, different methods have already been 
applied; the most commonly used method at our department is the 
incorporation of high molecular weight poly(lactic-co-glycolic acid)(HMW-
PLGA) microparticles to generate CaP/PLGA composites.9-12 A limitation 
regarding the use of PLGA for microparticle production is the relative slow 
degradation of this polymer (6-12 weeks).11 This slow degradation still prevents 
cells to penetrate into the implants early after in vivo application, which is the 
probable cause of delayed bone formation in the composites.9,12-14  
Therefore, a method was developed to prepare composites in which 
microparticles of gelatin were incorporated into CaP cement.15,16 Gelatin 
microparticles are biodegradable, biocompatible, and non-toxic and can be 
crosslinked with glutaraldehyde in order to increase thermal and mechanical 
stability of the microparticles under physiological conditions.17 Furthermore, 
the crosslinking agent concentration and reaction period can be varied, 
allowing the creation of microparticles with different degradation 
properties.17-19 
Inherent to the creation of porosity is the loss of mechanical strength of the 
CaP cement material. This makes the composites less suitable for use under 
load-bearing conditions. In an ideal situation, the cement would retain its 
mechanical strength, while being resorbed and replaced by newly formed 
bone. Previous research already showed that the decreased mechanical 
properties are partly compensated by the ingrowth of bone in the cement 
porosity.12  
To further stimulate bone formation and cement resorption, microparticles 
can be used for the delivery of an appropriate growth factor. Among the 
candidate growth factors for such an application is transforming growth 
factor β1 (TGF-β1), which plays a significant role in wound healing20-22 by 
enhancing the repair of injured tissue like skin and bone.23 TGF-β1 acts on 
osteoblasts, chondrocytes, and cells of the osteoclastic lineage24 and has 
been reported to stimulate osteogenesis at orthotopic sites.25-27 
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In view of the above mentioned, this study investigated the potential of TGF-
β1 loaded gelatin microparticles to enhance the bone response and 
mechanical strength of rabbit femoral defects filled with injectable 
CaP/gelatin microparticle composites. 
 
Materials & Methods 
Calcium phosphate (CaP) cement: 
CaP cement (Calcibon®; Biomet Merck, Darmstadt, Germany) was used for 
the preparation of the implants. The chemical composition of this cement is 
61% α-TCP, 26% CaHPO4, 10% CaCO3 and 3% PHA (α-TCP is α tri-calcium 
phosphate, PHA is precipitated hydroxyapatite). Before usage, the cement 
powder was sterilized by gamma radiation with 25 kGy (Isotron B.V., Ede, The 
Netherlands). 
 
Gelatin microparticles 
Gelatin microparticles were prepared as described by Holland et al.28. Briefly, 
a gelatin solution was prepared by dissolving negatively-charged acidic 
gelatin (type B; pI= 4.7-5.2; Sigma, St. Louis, MO, USA) in deionized water at 
37°C for 1 hour. Then, this solution was dropwise added to 125 ml chilled olive 
oil (Acros Organics, Geel, Belgium) while stirring at 500 rpm. After 30 min. of 
stirring, 50 ml chilled acetone (4°C; HPLC grade, Labscan Ltd., Dublin, Ireland) 
together with 500 µl 25 wt% glutaraldehyde (Merck, Darmstadt, Germany) 
was added to the emulsion. After an additional 30 min. of stirring, the 
microparticles were collected by filtration and washed with chilled acetone 
(4°C). Finally, the microparticles were frozen and lyophilized. 
Microparticle size distribution was assessed by morphometrical analysis using a 
light microscope (Leica Microsystems AG, Wetzlar, Germany) and computer 
based image analysis techniques (Leica® Qwin Pro-image analysis system, 
Wetzlar, Germany). 
 
TGF-β1 microparticle loading 
For the TGF-β1-loaded composites, 600 mg gelatin microparticles were 
swollen in 3.6 ml 4 mM HCl/BSA [0.1%] solution containing 10 µg TGF-β1 (R&D 
Systems Minneapolis, MI, USA), vortexed and lyophilized again. This solution 
volume is below the microparticles’ theoretical swelling volume in order to 
allow complete growth factor adsorption. In this way, the positively charged 
TGF-β1 formed a polyionic complexation with the negatively charged gelatin 
microparticles.29 Eventually, 250 ng TGF-β1 was present within each implant. 
 
Injectable CaP/gelatin composites 
Composites containing 5% (w/w) gelatin microparticles were generated as 
follows. Gelatin microparticles (30 mg), either or not loaded with TGF-β1, were 
pre-swollen in 180 µl water and mixed for 15 sec in a 2 ml syringe (Sherwood 
medical monoject) with closed tip using a mixing apparatus (Silamat, 
Vivadent, Schaan, Liechtenstein) to obtain an even distribution of the water 
content in the microparticles. CaP cement powder (570 mg) was added 
afterwards in the 2 ml syringe. The final composite was created by mixing 210 
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μl of Na2HPO4 (1 wt%; filter-sterilized) with 600 mg of this CaP/gelatin 
combination for 15 sec using the mixing apparatus. After mixing, the cement 
was immediately injected into the defect. 
Final composite formulations in this study were: 
1) CaP/gelatin (5% w/w gelatin microparticles/calcium phosphate 
cement composite) 
2) CaP/gelatin+TGF-β1 (5% w/w TGF-β1-loaded gelatin 
microparticles/calcium phosphate cement composite; 250 ng TGF-β1 
per composite) 
Furthermore, additional samples were prepared with the goal to determine 
the total porosity of the composites by correlating the weight of CaP samples 
with the weight of the CaP/gelatin samples after placement in a furnace at 
650°C for 2 hours (to remove the gelatin microparticles).11  
 
Surgery 
Thirty-six female New Zealand White rabbits (4-5 months) with a weight of 
approximately 3.5 kg were used as experimental animals. The animal 
experiment was approved by the Animal Ethical Committee of the Radboud 
University Nijmegen Medical Center and national guidelines for the care and 
use of laboratory animals were observed. Each rabbit received only one 
sample of both CaP/gelatin composite formulations. The composites were 
inserted in trabecular bone defects as created in the left medial and right 
medial distal femur.30 In this way, 72 composites were injected in thirty-six 
rabbits.  
Surgery was performed under general inhalation anesthesia. Anesthesia was 
induced by an intravenous injection of Hypnorm (0.315 mg/ml fentanyl citrate 
and 10 mg/ml fluanisone) and atropine, and maintained by a mixture of 
nitrous oxide, isoflurane, and oxygen through a constant volume ventilator. To 
reduce the peri-operative infection risk, the rabbits received antibiotic 
prophylaxis (Baytril 2.5% (enrofloxacin), 5–10 mg/kg).  
During anesthesia, the rabbits were immobilized on their back and the 
surgical areas were shaved and disinfected with povidone-iodine. A 
longitudinal incision was made down to the periosteum. Subsequently, a 
midline incision was created in the periosteum. The periosteum was 
undermined and lifted off the distal femora. The defects in the femora were 
drilled from the medial direction with an increasing burr diameter (from 2.0 to 
4.0 mm) to obtain cylindrical defects with a depth of 6 mm and a diameter of 
4 mm. Following injection of the composites, the material was left to set for 
approximately 10 minutes. Subsequently, the periosteum and soft tissue were 
closed using resorbable Vicryl 4–0 sutures.  
The rabbits were sacrificed in groups of 12 at four, eight, and twelve weeks 
(n=12 per formulation at each time period) post-surgery by an overdose of 
Nembutals (pentobartital).  
 
Mechanical testing (i.e. push-out test) 
To determine the mechanical strength of the rabbit femoral defects filled with 
CaP/gelatin composites, half of the retrieved specimens (n=6 for each 
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composite formulation at each time point) were used. Evaluation consisted of 
a push out-test31,32, using a mechanical testing bench (MTS 858 Mini Bionix II, 
Gouda, The Netherlands). The retrieved specimens with their surrounding 
tissue were transported to the laboratory on ice. After arrival, the distal femur 
was grinded at both sides to obtain flat surfaces, with the composite implant 
perpendicular to these flat surfaces,.to make the push-out test possible. 
Subsequently, each specimen was fixated on a support jig with a hole of 4.4 
mm (10% larger than the implant diameter of 4.0 mm) to minimize the effect 
of the test condition on the push-out results.31,32 This support jig enabled the 
application of a vertical force using a 3.85 mm diameter lever (at a constant 
displacement speed of 0.5 mm/min) on the CaP/gelatin specimens including 
the new bone formation. When the peak force was reached, the test was 
immediately stopped to ensure minimal displacement of the samples. The 
mechanical strength of the defects filled with composites was calculated by 
following formula: 
 
 
Scanning Electron Microscopy (SEM) 
After mechanical testing, the specimens were fixated in 10% formalin solution, 
dehydrated in a graded series of ethanol, and embedded in 
methylmethacrylate. After polishing, the specimens were sputter-coated with 
gold, and examined with SEM (Jeol 6310 Scanning Electron Microscope, 
Boston, MA, USA) to determine the fracture plane as occurred during the 
push-out testing (e.g. in the cement, at the interface bone-cement, in the 
surrounding bone). SEM was performed at the Microscopic Imaging Center 
(MIC) of the Nijmegen Center for Molecular Life Sciences (NCMLS), the 
Netherlands. 
 
Histological and histomorphometrical evaluation 
The other half of the retrieved implants with their surrounding tissue (six 
specimens of each experimental group at each time point) were prepared 
for histological evaluation. The samples were fixated in 4% formalin solution 
(pH=7.4), dehydrated in a graded series of ethanol, and embedded in 
methylmethacrylate. Following polymerization, three 10 µm thick, longitudinal 
sections were prepared per specimen through the centre of the composites, 
using a sawing microtome technique.33 The sections were stained with 
methylene blue and basic fuchsin and investigated using a light microscope. 
For histomorphometrical analysis, all sections per specimen were evaluated 
using computer based image analysis software. (Leica® Qwin Pro-image 
analysis system, Wetzlar, Germany). The quantitative evaluation of newly 
formed bone was done by determining a region of interest (ROI), which was 
set using a circle of 4.0 mm in diameter with the composite positioned in the 
centre. Within this ROI, new bone formation was distinguished from composite 
through structure and color differences. New bone formation was expressed 
in mm2, using standardization of the 2-dimensional area of analysis. 
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Bone/implant contact evaluation was defined by the percentage of 
composite perimeter at which direct bone to composite contact, without an 
intervening soft tissue layer, was present. 
Degradation of the CaP/gelatin composites was determined by calculating 
the remaining surface area of the composites through structure and color 
differences. The remaining composite was expressed in mm2, using 
standardization of the 2-dimensional area of analysis. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using one-way analysis of 
variance (ANOVA) with a Tukey multiple comparison post-test. Significance 
was set at p<0.05. 
 
Results 
Composite characterization 
The distribution of the unswollen gelatin microparticles varied between 1 to 49 
µm with an average size of 8.4 ± 7.6 µm, while the water-swollen 
microparticles varied between 1 to 66 µm with an average size of 20.7 ± 14.6 
µm. The porosity of the composite formulations after setting was 45.0 ± 1.3 % 
(Table 1).     
 
Table 1: Implant porosity, 
gelatin microparticle sizes, 
and TGF-β1 loading. 
 
 
 
 
 
General observations of animals  
All thirty-six rabbits in this experiment remained in good health and did not 
show any wound complications after surgery. The original defects were 
completely filled with the injectable composites without the presence of 
entrapped air bubbles. At retrieval, no visual signs of inflammatory or adverse 
tissue reactions were observed. 
 
Mechanical testing 
The results of the push-out test (Figure 1) showed a gradual increase in 
mechanical strength with increasing implantation periods. After four weeks of 
implantation, the push-out value of the CaP/gelatin composites including 
new bone formation was 3.7 ± 1.7 MPa, which increased to 6.6 ± 1.6 MPa at 
eight weeks, and finally measured 10.0 ± 2.9 MPa after twelve weeks of 
implantation. The CaP/gelatin+TGF-β1 composites including new bone 
formation showed a mechanical strength value of  2.9 ± 0.7 MPa after four 
weeks of implantation, which increased to 4.9 ± 3.0 MPa at eight weeks, and 
finally measured 9.1 ± 3.6 MPa after twelve weeks of implantation. At 
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individual implantation periods, no significant differences of mechanical 
strength values were present between CaP/gelatin and CaP/gelatin+TGF-β1 
composite formulations. 
 
Figure 1: Push-out test results (in 
MPa) of CaP/gelatin composites 
with or without TGF-β1 after four, 
eight, and twelve weeks of 
implantation. Bars represent means 
± SD (n=6) 
 
 
 
 
 
 
 
 
Scanning Electron Microscopy (SEM) 
SEM examination (Figure 2) of the fracture plane of the specimens subjected 
to the mechanical test showed similar results for CaP/gelatin and 
CaP/gelatin+TGF-β1 composites. After four weeks of implantation, samples 
showed a fracture plane at the bone-cement interface (Figure 2A), while the 
eight week samples showed a fracture, which was found in the CaP/gelatin 
composites, as well as in the newly formed bone (Figure 2B). Finally, the 
twelve week samples demonstrated fractures only in the newly formed bone 
(Figure 2C). 
 
Histological and histomorphometrical evaluation 
Histological evaluation showed similar results for CaP/gelatin and 
CaP/gelatin+TGF-β1 composites (Figure 3). Within the first four weeks after 
implantation, limited bone formation occurred at the implant periphery, 
whereas after eight weeks of implantation peripheral microparticles were 
degraded and replaced by newly formed bone. Finally, after twelve weeks of 
implantation more bone ingrowth was observed deeper into the composites, 
but no tissue formation was present in the central part of the composites. 
Furthermore, degradation of the composites was observed, indicated by the 
loss of integrity of the implant and by the decline in composite diameter and 
concomitant replacement by newly formed bone with increasing 
implantation time. Also, this newly formed bone around the composites 
appeared to be denser than the surrounding trabecular bone. In three 
samples (out of 36), an intervening fibrous tissue layer was observed between 
composite and surrounding bone. One was found after eight weeks of 
implantation in the CaP/gelatin group, while the other two were found in the 
CaP/gelatin+TGF-β1 at four and eight weeks of implantation. None of the 
composites were associated with the presence of multi-nucleated giant cells. 
Histomorphometrical evaluation showed no significant differences between 
formulations containing CaP/gelatin or CaP/gelatin+TGF-β1 (Figure 4).  
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Figure 2: Scanning Electron Microscopy 
(SEM) of Cap/gelatin composites with or 
without TGF-β1 after four (A), eight (B) and 
twelve (C) weeks of implantation. CaP/Gel 
= calcium phosphate cement with 
incorporated gelatin microparticles; B = 
trabecular bone; F = fracture (plane); N = 
newly formed bone 
 
Figure 3: Histological sections of 
CaP/gelatin+TGF-β1 composites after four 
(A), eight (B), and twelve (C) weeks of 
implantation (dashed circle marks the 
original defect diameter) 
 
Bone ingrowth into the CaP/gelatin composites after four weeks of 
implantation was 0.6 ± 0.5 mm2, which increased to 1.8 ± 0.4 mm2 at eight 
weeks, and finally measured 2.2 ± 1.0 mm2 after twelve weeks of implantation. 
CaP/gelatin+TGF-β1 composites showed bone ingrowth of 1.0 ± 0.7 mm2 after 
four weeks of implantation, which increased to 1.7 ± 0.9 mm2 at eight weeks, 
and finally measured 3.8 ± 2.0 mm2 after twelve weeks of implantation. 
Bone/implant contact of the CaP/gelatin composites (Figure 5) after four 
weeks of implantation was 61.0 ± 11.4 %, which after eight weeks measured 
64.8 ± 15.1 %, and finally was 64.2 ± 15.8 % after twelve weeks of implantation. 
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CaP/gelatin+TGF-β1 composites showed a bone/implant contact of 54.6 ± 
10.2 % after four weeks of implantation, which after eight weeks measured 
62.9 ± 4.8 %, and finally was 53.7 ± 8.0 % after twelve weeks of implantation. 
The remaining surface area of the CaP/gelatin composites (Figure 6) after 
four weeks of implantation was 11.2 ± 1.0 mm2, which decreased to 9.2 ± 1.0 
mm2, and finally measured 7.7 ± 1.7 mm2 after twelve weeks of implantation. 
CaP/gelatin+TGF-β1 composites showed a remaining surface area of 10.4 ± 
1.0 mm2 after four weeks of implantation, which decreased to 8.4 ± 2.0 mm2 
at eight weeks, and finally measured 3.8 ± 2.3 mm2 after twelve weeks of 
implantation. The difference between CaP/gelatin composites and 
CaP/gelatin+TGF-β1 was significant after twelve weeks of implantation. 
 
 
Figure 4: Bone ingrowth (in mm2) into 
the CaP/gelatin composites with or 
without TGF-β1 after four, eight, and 
twelve weeks of implantation. Bars 
represent means ± SD (n=6) 
 
 
 
 
 
 
 
 
Figure 5: Bone/implant contact (in %) o
the CaP/gelatin composites with or 
without TGF-β1 after four, eight, and 
twelve weeks of implantation. Bars 
represent means ± SD (n=6) 
f 
re 6: Remaining surface area (mm2) 
i
 
 
 
 
 
 
 
 
 
Figu
of the CaP/gelatin composites with or 
without TGF-β1 after four, eight, and 
twelve weeks of implantation. Bars 
represent means ± SD (n=6). Asterisk (*) 
ndicates significant difference 
(p<0.05). 
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Discussion 
In this study, the bone response and mechanical strength of a rabbit femoral 
defect filled with an injectable CaP cement containing gelatin microparticles, 
either or not loaded with TGF-β1, was examined. The loading of gelatin 
microparticles with TGF-β1 was enrolled as a parameter to evaluate potential 
effects of this growth factor on bone formation and cement resorption.  
The porosity of both composite formulations (CaP/gelatin with or without TGF-
β1) was 45.0 ± 1.3%, which should be high enough to obtain an 
interconnective network after microparticle degradation.33 Nonetheless, no 
fibrous tissue or bone formation was observed in the central part of the 
implants. This might be due to the delayed degradation of gelatin 
microparticles in the central part of the composites, or the relatively low mass 
ratio of microparticles (5 wt%) in the composite formulations. The lack of 
interconnectivity might further be explained by the formation of apatite 
crystals on gelatin, which has been reported previously.15,34 This phenomenon 
might cause filling of the created pores with precipitate, and hence hamper 
the formation of an interconnective network. This problem can be solved 
partly by increasing the mass ratio, but we know also that setting problems 
occur if the mass ratio is above a certain threshold15, which makes such 
composite formulations unfavorable for clinical usage.  
In this study, implants were grinded to obtain a flat surface for the push-out 
test. Still, parameters like composite thickness, composite diameter, angularity 
of the bone defect and positioning of the lever can influence the results of 
the push-out test.31 Nevertheless, the push-out results represent an 
approximation of the actual mechanical strength. Remarkably, the results of 
the push-out test showed similar or even higher values compared to the 
compression strength of 4-10 MPa of trabecular bone.35-37 This observation is in 
accordance with Ikenaga et al.37, who also found massive new bone 
formation around degraded CaP cement, which was mainly composed of β-
TCP. This new bone formation resulted in an increased bone density directly 
around the degraded implant, and hence higher push-out values of the 
composites compared to trabecular bone. Furthermore, the applied push-out 
test utilizes a similar lever for all samples. In view of composite degradation 
and replacement by newly formed bone at later implantation periods, the 
used method is not testing the actual interface of the composite with the 
bone tissue of these samples, but rather the denser bone structure directly 
around the degraded composite. The increase in mechanical strength with 
implantation time was further confirmed by SEM examination, which evidently 
supports the suggestion that the composite appears to be suitable for load-
bearing purposes. 
Histological evaluation showed that bone ingrowth started at the defect 
edges and proceeded into the micropores, which were created after 
degradation of the gelatin microparticles. This was also observed in other in 
vivo experiments with CaP cement based composites.12,13,38 This might be due 
to the already excellent osteogenic properties of the CaP cement. Kroese-
Deutman et al.39 reported that porous CaP cement itself was sufficient to 
bridge a critical-sized cranial defect in rabbits, without the presence of any 
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growth factors. On the other hand, the cement material in their study did not 
show a clear sign of degradation despite the complete filling of the implant 
porosity with bone tissue. This is in contrast to the current study where the TGF-
β1 loaded specimens were significantly more degraded than the non-loaded 
specimens, which suggests that the released TGF-β1 evoked an enhanced 
bone remodeling resulting in increased cement degradation. 
Further, it has to be noticed that we decided to employ a dose of 250 ng TGF-
β1 (3.3 ng per mm3 implant) per injectable composite. Since the optimal TGF-
β1 concentration is unknown, the amount of included TGF-β1 was based on 
previous research.40 Amounts of 0.5 ng TGF-β1 per mm3 implant have been 
reported to have an effect on bone formation in a rat cranial defect.41 Also, 
Vehof et al.42 and Beck et al.43 both described the incorporation of up to 25 
ng TGF-β1 per mm3 implant to have an effect on bone formation in a rabbit 
cranial defect.  
Considering the release kinetics of TGF-β1 from the gelatin/CaP composite, 
previous research by Habraken et al.44 showed that the release of TGF-β1 
from gelatin microparticles incorporated in CaP cement was limited to 14%, 
and that the release of adsorbed TGF-β1 on CaP cement alone was limited to 
33% after 6 weeks of incubation. From literature, it is further known that CaP 
cements have a strong binding affinity for proteins.45,46 Most likely, after 
degradation of the gelatin microparticles, the released TGF-β1 was bound to 
the CaP cement, which after cement degradation was released again. 
Therefore, the released TGF-β1 is still able to stimulate the bone response after 
longer implantation periods. Besides, it is proposed that even in a biomaterial-
bound state, a growth factor can retain its biological activity.47,48  
Although almost all implants showed good bone ingrowth, three samples 
showed an intervening fibrous tissue layer between composite and 
surrounding bone. This could be explained by an initially suboptimal 
bone/implant contact, which can result in fibrous tissue formation.12 The 
added water inside the gelatin microparticles and the presence of body 
fluids can contribute to a delayed setting time.15,49 This hampers setting of the 
composite on the defects periphery, and can lead to composite material 
being flushed away at the bone defect wall. Although bleeding of the bone 
defects was tried to be minimized by packing the defects with gauzes before 
injecting the composites, the presence of limited amounts of blood at the 
defect site could not be completely prevented. 
The bone/implant contact measurements showed a contact of 
approximately 60% during all implantation periods. Ooms et al.7 reported that 
a CaP cement without microparticles resulted in a bone/implant contact of 
80-90%. By adding microparticles in the CaP cement the surface area of the 
CaP cement is increased after degradation of the microparticles. Therefore, 
new bone formation has to fill up the created pores, which might explain the 
differences in bone/implant contact with dense CaP cement. 
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Conclusions 
In conclusion, this study demonstrated that after injection and setting of a 
CaP/gelatin composite, the mechanical strength of the composite including 
the new bone formation, is sufficient after 12 weeks of implantation for load-
bearing purposes. Further, degradation of the composites was observed, 
indicated by the loss of integrity of the composites, and by the decline in 
composite diameter and concomitant replacement by newly formed bone 
with increasing implantation time. The addition of TGF-β1 to the gelatin 
microparticles in the composite formulation did not result in higher 
mechanical strength values or improvement of the bone response, but 
significantly increased composite degradation after twelve weeks of 
implantation. 
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Summary, address to the aims, closing remarks, and future 
perspectives 
Calcium phosphate (CaP) ceramics are widely used as bone substitutes in 
dentistry, orthopedics and reconstructive surgery, because of their 
biocompatibility and osteoconductivity. CaP ceramics are particulary 
promising as bone substitutes, due to their similarity to hydroxyapatite, the 
mineral component of bone. In addition to being non-toxic, they are 
biocompatible and exhibit bioactive behavior. Unfortunately, these ceramics 
are only available as prefabricated blocks or granules. Prefabricated blocks 
are difficult to shape, resulting in poor filling of the bone defect, while 
granules do not provide the dimensional stability and can easily migrate into 
the surrounding tissue. A solution for these problems can be a cement-like 
material that can be shaped according to the defect dimensions and 
hardens in situ. Already several studies have investigated the use of CaP 
cements as a potential scaffold material for bone tissue engineering. 
Although the achieved results hold promise, the clinically perfect material is 
not available yet. Therefore, many variables such as, injectability, setting time, 
porosity, mechanical properties, polymeric additives and inclusion of growth 
factors as well as their release need to be investigated.   
Therefore, the general aim of the current project was the further development 
of an injectable self-setting CaP cement as a appropriate scaffold material 
for bone tissue regeneration. This bone substitute should possess a porous 
structure to allow tissue ingrowth, and should show gradual resorption to allow 
substitution by autologous bone. Furthermore, the intrinsic osteogenic 
properties of the CaP cement have to be extra enhanced by the inclusion of 
polymeric microparticles with a time-dependent release of bone 
regenerating factors. 
 
Investigation of the in vitro cytocompatibility of CaP cement as 
a scaffold material for a cell-based tissue engineering approach. 
In chapter two, the cytocompatibility and early osteogenic characteristics of 
rat bone marrow cells (RBM) on injectable calcium phosphate (CaP) cement 
were investigated. 
Besides unmodified CaP cement discs, two different additional treatments 
were given to the discs, preincubation in MilliQ and sintering at different 
temperatures. The results showed that CaP discs without any additional 
treatment were not supporting osteoblast-like cells in vitro. Preincubating discs 
in MilliQ for periods of 1, 4, 8 and 12 weeks resulted in the hydrolysis of α-TCP 
(Tri Calcium Phosphate) into a apatite-like structure with some β-TCP as shown 
with XRD, but still the material was not cytocompatible. Sintering the discs 
between 800°C and 1100°C resulted in conversion of α-TCP to β-TCP with 
some hydroxyapatite and an increase in crystallinity. Eventually, the 1100°C 
sintered discs resulted in superior cell attachment, abundant cell proliferation 
and early differentiation compared to other sintered (600°C, 800°C and 
1000°C), preincubated and unmodified specimens. This study indicates that in 
vivo results with CaP based cements do not guarantee their in vitro 
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applicability. Further, unmodified CaP cement is not cytocompatible in vitro, 
although preincubation of the material results in a more favorable cell 
response, sintering of the material at 1100°C is resulting in the best osteogenic 
properties. In contrast to in vivo studies, the CaP cement is not suitable as a 
scaffold for cell-based tissue-engineering strategies.  
 
Investigation of the biocompatibility of calcium phosphate 
cement/PLGA microparticle composites. 
In chapter three, the biocompatibility of a calcium phosphate (CaP) cement 
incorporating poly (D,L-lactic-co-glycolic acid) (PLGA) microparticles was 
evaluated in a subcutaneous implantation model in rats. The short-term 
biocompatibility results showed a mild tissue response for all implant 
formulations, irrespective of disc preincubation, during the early implantation 
periods up to 12 days. The results concerning long-term biocompatibility 
showed that all implants were surrounded by a thin connective tissue capsule 
(<10 layers of fibroblasts). The implants containing 20% PLGA with medium- 
and large-sized microparticles showed fibrous tissue ingrowth throughout the 
implants, indicating PLGA degradation and interconnectivity of the pores. The 
results of the present study demonstrate that CaP/PLGA composites evoke a 
minimal inflammatory response. The implants containing 20% PLGA with 
medium- and large-sized microparticles showed fibrous tissue ingrowth 
throughout the implants after 12 and 24 weeks indicating PLGA degradation 
and interconnectivity of the pores. Therefore, CaP/PLGA composites can be 
regarded as biocompatible biomaterials with huge potential for bone tissue 
engineering and advantageous possibilities of the microparticles regarding 
material porosity and drug delivery. 
 
Investigation to prove that in vivo bone ingrowth results in an 
increase of mechanical strength of implanted CaP/PLGA 
composites. 
In chapter four, the mechanical properties of implanted calcium phosphate 
(CaP) cement incorporated with 20 wt% poly (DL-lactic-co-glycolic acid) 
(PLGA) microparticles were investigated in a rat cranial defect. It was 
concluded that the shear strength of the bone-cement interface increased 
over time due to bone ingrowth into the CaP/PLGA composites. Although the 
bone-cement contact could be optimized with an injectable CaP cement to 
enhance bone ingrowth, still the mechanical properties of the composites 
after 8 weeks of implantation appeared to be insufficient for load bearing 
purposes.  
 
Investigation of the bone augmentation properties of an 
injectable CaP/PLGA composite either or not loaded with TGF-
β1 in vivo.  
In chapter five, the bone augmentation properties of an injectable 
composite consisting of CaP/PLGA, and the additional effect of loading 
PLGA microspheres with TGF-β1 was examined. For this purpose, CaP/PLGA 
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composites and CaP/PLGA composites loaded with TGF-β1 were injected on 
top of the skulls of Wistar rats. After 2, 4, and 8 weeks the results were 
evaluated histologically and histomorphometrically. The contact length 
between the implants and newly formed bone increased in time, and it was 
significantly higher for the TGF-β1 composites after 2 weeks. Also, bone 
formation was significantly higher for the TGF-β1 composites (18.5% ± 3) 
compared to controls (7.21% ± 5) after 8 weeks of implantation. The 
immunohistochemical staining demonstrated massive inflammatory infiltrate 
in both groups, particularly at 2 weeks, which decreased substantially at 4 
and 8 weeks. In conclusion, the injectable CaP/PLGA composite stimulated 
bone augmentation in a rat model. The addition of TGF-β1 to the composite 
significantly increased bone contact at 2 weeks and enhanced new bone 
formation at 8 weeks. 
 
Investigation of the in vivo degradation properties and 
subsequent bone formation of implanted CaP/gelatin 
composites. 
In chapter six, the degradation properties of gelatin microparticles 
incorporated in calcium phosphate (CaP) cement and the subsequent effect 
of these composites on bone formation was evaluated. Positively charged 
alkaline gelatin (type A) microparticles and negatively charged acidic 
gelatin (type B) microparticles were incorporated in CaP cement, which was 
implanted in critical-sized cranial defect in rats and left in place for two, four 
and eight weeks. The degradation of the gelatin was monitored using 
radioiodinated microparticles. After four and eight weeks of implantation, a 
significant faster degradation of type A gelatin over type B gelatin was found. 
Light microscopic analysis of the specimens showed similar bone response 
concerning implants containing either type A or B gelatin microparticles. At 
two weeks of implantation, a minimal amount of bone formation occurred 
from the cranial bone towards the implant, while after eight weeks of 
implantation a layer of newly formed bone was present from the cranial bone 
towards the implant periphery. Bone ingrowth into the implant was observed 
in degraded gelatin microparticles predominantly at the implant periphery. 
In conclusion, this study demonstrates that gelatin type influences the 
degradation of gelatin microparticles incorporated in CaP cements. 
However, this difference in degradation and the concomitant subsequent 
macroporosity did not induce differences in the biological response. 
 
Investigation of the in vivo bone response and mechanical 
strength of an injectable CaP/gelatin composite either or not 
loaded with TGF-β1.   
Chapter seven focused at the potential of TGF-β1 loaded gelatin 
microparticles to enhance the bone response and mechanical strength of 
rabbit femoral defects filled with injectable CaP/gelatin microparticle 
composites. Therefore, TGF-β1 loaded composites and non-loaded controls 
were injected in circular defects as created in the femoral condyles of rabbits 
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and were left in place for four, eight, and twelve weeks. The results showed a 
gradual increase in mechanical strength with increasing implantation periods. 
Histological and histomorphometrical evaluation showed similar results for 
both composite formulations regarding histological aspect, new bone 
formation and bone/implant contact. However, TGF-β1 loading of the 
composites demonstrated a significant effect on composite degradation 
after twelve weeks of implantation. The results of this study showed that 
CaP/gelatin composites demonstrated excellent osteogenic properties and a 
rapid increase in mechanical strength. The addition of TGF-β1 significantly 
enhanced the bone remodeling process. 
 
Closing remarks & future perspectives 
The experiments described in this thesis deal with the further development of 
an injectable self-setting CaP cement as an appropriate scaffold material for 
bone tissue regeneration. Previous in vivo research with pre-set CaP cement 
implants already showed excellent bone compatibility. Evidently, the CaP 
cement was proven to be osteoconductive, but not inductive. To improve the 
osteogenic properties, cells can be encapsulated and included in the 
cement in order to improve the biological response. However, the first study in 
this thesis proved that CaP cement was not cytocompatible in vitro, and 
therefore currently not suitable as a scaffold for cell-based tissue-engineering 
strategies. Although, in vitro cell studies cannot be extrapolated implicitly to 
the in vivo situation, cell encapsulation in the CaP cement seems not to be an 
option with the presently available material.  
Subsequently, in vivo experiments were performed to determine the overall 
biocompatibility of the CaP cement. Pre-set samples were placed 
subcutaneously in rats, where they evoked only a mild inflammatory response. 
Therefore, instead of including bone-forming cells, it was decided to proceed 
with the addition of growth factors into the cement in order to improve the 
osteogenic properties of this material. To achieve this, the approach for the 
incorporation and release of growth factors has to be adjusted, since earlier 
studies already showed that a limited amount of growth factors is released 
due to the strong protein-binding affinity of the CaP cement. 
Furthermore, cement degradation remains a point of concern. Previous 
research at our department with a CO2-gas bubble method indicated that 
cement degradation was enhanced with an increasing porosity, due to a 
higher specific surface area of the cement, but the created pores were 
irregular shaped and mechanical properties decreased to very low levels. As 
described in this thesis, this problem can be overcome by introducing PLGA or 
gelatin microparticles into the CaP cement, which after degradation 
generate a more controlled porosity in the cement, while manageable 
mechanical properties are maintained. However, these PLGA-
gelatin/composites still lack sufficient mechanical properties for load bearing 
purposes. Therefore, an optimum balance between mechanical properties 
and porosity has to be investigated in future studies. 
On the other hand, both PLGA and gelatin microparticles proved to be 
suitable for incorporation into the cement without having a negative effect 
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on cement setting or evoking a negative tissue response. The polymeric 
microparticles degrade, which results in the creation of porosity inside the 
CaP cement. However, the degradation rate of the microparticles has to be 
enhanced to obtain faster bone formation inside the cement. Changing the 
molecular weight of PLGA, or the crosslinking parameters of gelatin can be 
topics of future research, since these are the main parameters responsible for 
the degradation rate of the microparticles. Furthermore, it was proven that 
the incorporated microparticles could be loaded with growth factors to 
stimulate bone formation and to increase cement resorption.  
In the last experiment of this thesis, injected CaP/gelatin composites 
demonstrated after twelve weeks of implantation, similar or even higher 
mechanical properties as compared to trabecular bone. This was due to 
degradation of the CaP/gelatin composites, and concomitant replacement 
by newly formed bone with increasing implantation times. This suggests that 
the composites under certain conditions can be applied in load-bearing 
situations.  
In conclusion, the obtained data are very promising, although future research 
has to focus on more improvements. First of all, the degradation of the 
microparticles has to be enhanced to allow rapid penetration of bone-
forming cells into the CaP cement, which can as well overcome the 
mechanical weakness of the cement. Also, after degradation of the 
microparticles a fully interconnected network should exist in order to allow 
through and through penetration of bone. The inclusion of multiple types of 
growth factors into the CaP cement is another issue that needs investigation. 
For example, combination of growth factors resulting in osteoinduction (e.g. 
BMP-2, BMP-7) and angiogenesis (VEGF) can be assessed. Next to 
osteoinduction, vascularization is important for bone formation, since it 
provides the transport of nutrients and waste, and the deliverance of 
osteoprogenitor cells to the core of the implants. Furthermore, research has to 
focus on the reduction of the included amount of growth factors. From a 
biological (safety) point of view as well as cost effectiveness, they have to be 
limited according physiological concentrations, rather than the massive 
amounts as currently used. This can be achieved by a more efficient delivery 
system, like by incorporating a combination of various polymeric 
microparticles with different degradation properties.   
Finally, the performance of a human experiment with CaP cement and 
incorporated microparticles has to be initiated. All experimental animal 
studies till now have confirmed that the CaP cement with the incorporated 
degradable microparticles is evidently bone biocompatible and 
osteoconductive. As extrapolation of animal studies to the human situation is 
always difficult, a human clinical trial appears now warranted so that not only 
final information is obtained about the bone substituting potential of this 
material, but also next steps can be set in the further development of this 
material.   
Overall, it can be concluded that the developed injectable CaP cement 
hold a promising future regarding the reconstruction of bone defects. 
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Samenvatting 
Calcium fosfaat (CaP) keramieken worden intensief gebruikt op het gebied 
van tandheelkunde, orthopedie en reconstructieve chirurgie, vanwege hun 
biocompatibiliteit en osteoinductiviteit. CaP keramieken zijn veelbelovend in 
het gebruik als botvervangers, door hun gelijkenis tot hydroxyapatiet, de 
minerale component van bot. Ze zijn biocompatibel en vertonen bioactief 
gedrag. Helaas zijn deze keramieken momenteel alleen verkrijgbaar als 
blokken of korrels. Doordat blokken moeilijk vorm te geven zijn, resulteert dat 
in een onvolledige vulling van een botdefect. Verder hebben korrels geen 
stabiliteit, waardoor ze gemakkelijk in het omliggende weefsel migreren. Een 
oplossing voor dit probleem zou een CaP cement kunnen zijn wat naar de 
dimensies van een botdefect gevormd kan worden en vervolgens uithardt. Er 
zijn al verscheidene studies geweest die CaP cement als een mogelijk 
materiaal voor bot tissue engineering onderzocht hebben. Hoewel de 
behaalde resultaten veelbelovend zijn, is de veiligheid en de betrouwbare 
heling van grote bot defecten nog niet bereikt. Daartoe dienen verschillende 
variabelen zoals injecteerbaarheid, uithardingstijd, porositeit, mechanische 
eigenschappen, polymere toevoegingen en groeifactor concentratie en 
afgifte onderzocht worden om zo tot een succesvol bot tissue engineered 
construct te komen. 
De algemene doelstelling van dit project is derhalve het produceren van een 
injecteerbaar, zelf-uithardend CaP cement voor toepassing in bot tissue 
engineering. Dit bot vervangende materiaal zou een poreuze structuur 
moeten hebben om weefsel ingroei alsmede een geleidelijk resorptie te 
bevorderen, waardoor vervanging door autoloog bot mogelijk wordt. 
Bovendien kunnen de intrinsieke osteogene eigenschappen extra 
gestimuleerd worden door de toevoeging van polymere micropartikels met 
een tijdsafhankelijke afgifte van groeifactoren. 
 
Onderzoek naar de in vitro celcompatibiliteit van CaP cement 
als een drager material voor een cel-gebaseerde tissue 
engineering benadering.  
In hoofdstuk 2 worden de celcompatibilieit en de vroege osteogene 
eigenschappen van rat beenmergcellen (RBM) op injecteerbaar calcium 
fosfaat (CaP) cement onderzocht. 
Naast onbehandelde CaP cement schijfjes, worden twee verschillende extra 
behandelingen aan de schijfjes onderzocht, namelijk preincuberen in MilliQ 
en sinteren op verschillende temperaturen. De resultaten laten zien dat CaP 
schijfjes zonder toegevoegde behandeling de osteoblast-achtige cellen niet 
ondersteunen in vitro. Preincubatie van schijfjes in MilliQ voor perioden van 1, 
4, 8 of 12 weken, resulteerde in de hydrolyse van α-TCP (tri calcium fosfaat) in 
een apatite-achtige structuur met enig β-TCP, hetgeen werd aangetoond 
met XRD. Echter, deze behandeling maakte het materiaal nog steeds niet 
celcompatibel. Sinteren van de schijfjes op 800°C of 1100°C resulteerde in 
een omzetting van α-TCP naar β-TCP met enige hydroxyapatiet vorming en 
een toegenomen kristalliniteit. Tenslotte resulteerde de op 1100°C gesinterde 
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schijfjes in een superieure celhechting, overvloedige celproliferatie en vroege 
differentiatie vergeleken met andere gesinterde (600°C, 800°C, 1000°C), 
gepreincubeerde en onveranderde schijfjes. Deze studie toont aan dat in 
vivo resultaten met CaP gebaseerde cementen niet vanzelfsprekend van 
toepassing zijn in vitro. Verder is CaP cement zonder enige additionele 
behandeling niet cytocompatibel in vitro. Hoewel preincuberen van het 
materiaal resulteert in een gunstige cel response,  leidt sinteren van het 
materiaal op 1100°C tot de beste expressie van osteogene eigenschappen. 
In tegenstelling tot in vivo studies lijkt het CaP cement niet geschikt als 
materiaal voor cel gebaseerde tissue engineering toepassingen. 
 
Onderzoek naar de in vivo biocompatibiliteit van CaP 
cement/PLGA micropartikel composieten. 
In hoofdstuk 3 werd de biocompatibiliteit van calcium fosfaat (CaP) cement 
met polymelkzuur (PLGA) micropartikels onderzocht in een subcutaan model 
in ratten. De korte-termijn biocompatibiliteitsresultaten lieten een milde 
weefsel reactie zien voor alle implantaten tijdens de vroege implantatie 
perioden tot 12 dagen, onafhankelijk van CaP cement preincubatie. De 
resultaten van de lange-termijn biocompatibiliteit toonden dat alle 
implantaten omringd waren door een dun bindweefsel kapsel (<10 lagen 
fibroblasten). De resultaten van deze studie laten zien dat CaP/PLGA 
implantaten een minimale ontstekingsreactie opwekken. De implantaten met 
20% PLGA middel en grote micropartikels bevatten vertoonden ingroei van 
fibreus weefsel door het hele implantaat heen, hetgeen duidt op PLGA 
degradatie en interconnectiviteit van de poriën. Concluderend, kunnen 
CaP/PLGA composieten beschouwd worden als biocompatibele 
biomaterialen met groot potentieel voor toepassing in bot tissue engineering 
en gunstige mogelijkheden van de micropartikels betreffende de materiaal 
porositeit en medicijn afgifte.  
 
Onderzoek naar het effect van in vivo bot ingroei op de 
mechanische sterkte van geïmplanteerde CaP/PLGA 
composieten. 
In hoofdstuk 4 werden de mechanische eigenschappen van geimplateerd 
calcium fosfaat (CaP) cement met 20% polymelkzuur (PLGA) micropartikels in 
een ratten schedeldak defect onderzocht. Er werd geconcludeerd dat de 
hechtingskracht van de bot-cement scheiding was toegenomen door de bot 
ingroei in de CaP/PLGA composieten bij een toenemende implantatietijd. 
Hoewel, een geïnjecteerd CaP cement het bot-cement contact zou 
optimaliseren, hetgeen zou leiden tot een verhoogde botingroei. Echter, de 
mechanische sterkte van de composieten na 8 weken van implanteren lijkt 
niet voldoende te zijn voor belastbare doeleinden. 
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Onderzoek naar de botvermeerderings potentieel van een 
geïnjecteerd CaP/PLGA composiet in vivo, al dan niet geladen 
met TGF-β1. 
In hoofdstuk 5 werden de botvermeerderings potentieel van een 
geïnjecteerd CaP/PLGA composiet, en het toegevoegde effect van TGF-β1 
geladen PLGA micropartikels onderzocht. Voor dit doel werden CaP/PLGA 
composieten en CaP/PLGA composieten geladen met TGF-β1 bovenop het 
schedeldak van Wistar ratten geïnjecteerd. Na 2, 4 en 8 weken werden de 
resultaten histologisch en histomorfometrisch geëvalueerd. De contactlengte 
tussen de implantaten en het nieuw gevormde bot was gedurende de tijd 
toegenomen, en het was significant hoger voor de TGF-β1 composieten na 2 
weken. Ook was de botformatie significant hoger voor de TGF-β1 
composieten (18,5% ± 3) vergeleken met de controles (7.21% ± 5) na 8 weken 
van implanteren. De immunohistochemische kleuring liet zien dat 
ontstekingsinfiltraat vooral aanwezig was na 2 weken, waarna de 
ontstekingsreactie substantieel afnam na 4 en 8 weken. Concluderend kan 
gesteld worden dat het injecteerbare CaP/PLGA composiet de botaanmaak 
in een rat model stimuleert. De toevoeging van TGF-β1 aan het composiet 
verhoogt significant het botcontact na 2 weken en verhoogt de botformatie 
na 8 weken. 
 
Onderzoek naar de in vivo degradatie en daaropvolgende 
botformatie van geïmplanteerde CaP/gelatine composieten. 
In hoofdstuk 6 werden de degradatie eigenschappen van gelatine 
micropartikels die toegevoegd waren aan een calcium fosfaat (CaP) 
cement geëvalueerd en het daaropvolgende effect van deze composieten 
op de botformatie onderzocht. Positief geladen gelatine (type A) 
micropartikels of negatief geladen gelatine (type B) micropartikels werden 
toegevoegd aan CaP cement, dat hierna werd geïmplanteerd in een 
kritisch-grootte schedeldak defect in ratten voor implantatie perioden van 
twee, vier en acht weken. De degradatie van het gelatine werd gevolgd met 
radioactief gejodeerde micropartikels. Na vier en acht weken van 
implantatie werd er een significant snellere degradatie gevonden van type A 
gelatine ten opzichte van type B gelatine. Licht microscopie analyse van de 
implantaten liet zien dat er een gelijke botresponse was betreffende de 
implantaten met type A alsmede type B gelatine micropartikels. Na twee 
weken van implantatie was er een minimale hoeveelheid bot gevormd van 
het schedelbot naar de implantaat periferie toe. Verder werd botingroei in 
het implantaat waargenomen in gedegradeerde gelatine micropartikels, 
overwegend in de implantaat periferie. 
Samenvattend toont deze studie aan dat het type gelatine de degradatie 
van de gelatine micropartikels in CaP cement beïnvloedt. Echter, dit verschil 
in degradatie en de daaropvolgende macroporositeit leidt niet tot het 
veroorzaken in verschillen in de biologische response. 
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Onderzoek naar de in vivo bot respons en mechanische sterkte 
van een injecteerbaar CaP/gelatine composiet, al dan niet 
geladen met TGF-β1.  
Hoofdstuk 7 benadrukt het potentieel van TGF-β1 geladen gelatine 
micropartikels om de bot response en de mechanische sterkte van konijn 
femorale defecten gevuld met injecteerbaar CaP/gelatine micropartikel 
composieten te verhogen. Daartoe werden TGF-β1 geladen composieten en 
niet geladen controles geïnjecteerd in circulaire defecten in femorale 
condylen van konijnen voor implantatie perioden van vier, acht en twaalf 
weken. De resultaten toonden een geleidelijke toename in mechanische 
sterkte met toenemende implantatie perioden. Histologische en 
histomorfometrische evaluatie lieten dezelfde resultaten zien voor beide 
composiet formulaties betreffende histologisch aspect, nieuw bot formatie en 
bot/implantaat contact. Echter, de composieten met TGF-β1 lieten een 
significant effect op composiet degradatie na twaalf weken van implantatie 
zien. De resultaten van deze studie lieten zien dat CaP/gelatine composieten 
uitstekende osteogene eigenschappen vertonen met een snelle toename in 
mechanische sterkte. De toevoeging van TGF-β1 verhoogde significant het 
bot remodelleringsproces. 
 
Afsluitende opmerking & toekomst perspectieven 
De experimenten die in dit proefschrift beschreven zijn behandelen de 
creatie van een injecteerbaar, zelf-uithardend CaP cement als een geschikt 
materiaal voor bot tissue engineering. Voorafgaand in vivo onderzoek met 
voor-uitgeharde CaP cement implantaten lieten al een uitstekende 
botcompatibiliteit zien. Het is bewezen dat het CaP cement osteoconductief 
is, maar niet inductief. Door cellen in te kapselen en aan het CaP cement toe 
te voegen, kunnen de osteogene eigenschappen verbeterd worden. Echter, 
de eerste studie in dit proefschrift heeft bewezen dat het CaP cement niet 
celcompatibel in vitro was en daardoor momenteel niet geschikt is als een 
drager voor cel-gebaseerde tissue engineering toepassingen. Hoewel in vitro 
cel studies niet onvoorwaardelijk geëxtrapoleerd kunnen worden naar de in 
vivo situatie, lijkt celinkapseling in het CaP cement niet een optie met het 
huidige beschikbare materiaal. 
Hieropvolgend zijn in vivo experimenten uitgevoerd om de biocompatibiliteit 
van het CaP cement te bepalen. Voor-uitgeharde implantaten zijn 
subcutaan in ratten geplaatst, waar ze alleen een milde ontstekingsreactie 
opwekten. Daardoor werd, in plaats van het incorporeren van botvormende 
cellen, de beslissing genomen om verder te gaan met het toevoegen van 
groeifactoren aan het cement om zo de osteogene eigenschappen te 
verbeteren. Om dit te bereiken, moest de benadering voor het insluiten en 
afgeven van groeifactoren worden aangepast, aangezien eerdere studies 
reeds hebben aangetoond dat slechts een beperkte hoeveelheid 
groeifactoren wordt afgegeven als gevolg van de sterke bindingscapaciteit 
van het CaP cement. 
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Bovendien blijft cement degradatie een zorgelijk punt. Voorafgaand 
onderzoek op onze afdeling met een CO2-gasbel methode liet zien dat 
cement degradatie wordt verhoogd als gevolg van toegenomen porositeit, 
door middel van een hogere specifieke oppervlakte van het cement. Echter, 
doordat de ontstane poriën willekeurig van vorm waren, nam de 
mechanische sterkte dramatisch af. Zoals beschreven in dit proefschrift werd 
dit probleem opgelost door het introduceren van PLGA of gelatine 
micropartikels in het CaP cement, hetgeen na degradatie een meer 
gecontroleerde porositeit in het cement opleverde met behoud van 
hanteerbare mechanische eigenschappen. Echter, de PLGA of gelatine 
composieten hebben nog steeds inferieure mechanische eigenschappen 
voor belastbare toepassingen. Daarom zal een optimale balans tussen de 
mechanische eigenschappen en porositeit in toekomstige studies onderzocht 
moeten worden.     
Van de andere kant hebben zowel PLGA als gelatine micropartikels bewezen 
dat ze geschikt zijn voor het toevoegen aan cement zonder een negatief 
effect op cement uitharding of een weefselreactie. De polymere 
micropartikels degradeerden, waardoor porositeit binnenin het CaP cement 
ontstond. Echter, de degradatiesnelheid van de micropartikels zal moeten 
worden verhoogd om een snellere botformatie binnenin het cement te 
krijgen. Het veranderen van het moleculaire gewicht van PLGA of de 
kruisverbindingen van gelatine zouden onderwerp kunnen zijn voor 
toekomstige onderzoeken, omdat vooral deze parameters verantwoordelijk 
zijn voor de degradatiesnelheid van de micropartikels. Bovendien is bewezen 
dat de toegevoegde micropartikels geladen kunnen worden met 
groeifactoren om zo de botformatie te stimuleren en cement resorptie te 
verhogen. 
In het laaste experiment van deze thesis lieten geïnjecteerde CaP/gelatine 
composieten na twaalf weken van implantatie gelijke of zelfs hogere 
mechanische eigenschappen dan trabeculair bot zien. Dit was het gevolg 
van de degradatie van CaP/gelatine composieten, en de daaropvolgende 
vervanging door nieuw bot in de tijd. Dit suggereert dat de composieten 
onder bepaalde condities aangewend zouden kunnen worden voor 
belastbare situaties. 
Samenvattend zijn de verkregen data veelbelovend, hoewel toekomstig 
onderzoek zich moet richten op verdere verbeteringen. Ten eerste, de 
degradatie van de micropartikels zal moeten worden verbeterd om een 
snelle penetratie van botvormende cellen in het CaP cement te 
bewerkstelligen, welke ook de mechanische zwakte van het materiaal kan 
ondervangen. Ook na degradatie van de micropartikels zou er een volledig 
verbindend netwerk moeten bestaan om zo penetratie van nieuw bot toe te 
laten. Het toevoegen van meedere types groeifactoren aan het CaP cement 
is een andere kwestie welke nog onderzocht moet worden. Een combinatie 
van groeifactoren leidend tot zowel osteoinductie (b.v. BMP-2, BMP-7) als 
bloedvatvorming (VEGF) kan in dat opzicht interessant zijn. Naast 
osteoinductie is vascularisatie belangrijk voor de botvorming, omdat het de 
aanvoer van voedingsstoffen en de afvoer van afvalstoffen mogelijk maakt, 
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en botvoorloper cellen naar het centrum van het implant kan aanvoeren. 
Bovendien moet onderzoek zich richten op de vermindering van de 
toegevoegde hoeveelheid groeifactoren. Vanuit een biologisch oogpunt en 
alsmede in het licht van kosten-baten moeten groeifactor concentraties 
verminderd worden tot minimale, klinisch relevante concentraties, in plaats 
van de enorme hoeveelheden die op het moment gebruikt worden. Dit kan 
bereikt worden door een effectiever afgifte systeem middels het toevoegen 
van een combinatie van verschillende polymere micropartikels met 
verschillende degradatie eigenschappen. 
Tenslotte zou de uitvoering van een humaan experiment met CaP cement en 
toegevoegde micropartikels gestart kunnen worden. Alle dierexperimentele 
studies tot nu toe hebben bevestigd dat het CaP cement met de 
toegevoegde degradeerbare micropartikels bot biocompatibel en 
osteoconductief te zijn. Hoewel extrapolatie van dierstudies naar de humane 
situatie altijd moeilijk is, lijkt een humaan klinisch proefexperiment nu 
gerechtvaardigd. Hierdoor wordt niet alleen definitieve informatie verkregen 
over het botvervangende potentieel van dit materiaal, maar kunnen ook 
vervolgstappen gemaakt worden in de verdere ontwikkeling van dit 
materiaal voor klinisch toepassingen. 
Als eindconclusie kan gesteld worden dat het ontwikkelde injecteerbare CaP 
cement een veelbelovende toekomst heeft betreffende de reconstructie van 
bot defecten.   
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Dankwoord 
Bij het begin van mijn promotie traject dacht ik dat onderzoek doen echt iets 
was wat je vooral zelf uitvoerde. Bleek ik daar even naast te zitten! Het feit 
dat deze lijst al behoorlijk lang is geworden zegt wel iets over de 
betrokkenheid van de verscheidende personen aan het tot stand komen van 
dit proefschrift. Ook wil ik iedereen bedanken die in de loop der jaren 
interesse heeft getoond naar het reilen en zeilen van mijn onderzoek. In het 
bijzonder wil ik de volgende personen bedanken:  
 
Prof. Dr. Jansen, Beste John, ontzettend bedankt dat ik deze mogelijkheid 
heb gehad om op jouw afdeling te mogen promoveren! Ondanks dat je een 
erg druk bezet man bent, bleef je toch de regie van het onderzoeksproject in 
handen houden en zorgde je ervoor dat de vaart erin bleef. Ook de 
mogelijkheid die je gaf om in Houston onderzoek te verrichten, werd 
uiteindelijk een zeer leerzame ervaring voor mij. Verder bleef mij ook keer op 
keer je parate kennis en de snelheid waarmee je werkt verbazen. Zelfs die 
ene keer dat ik op zaterdagavond een mail stuurde had ik in no-time 
antwoord terug, en was het desbetreffende onderwerp nog (goed) 
gecorrigeerd ook! 
 
Dr. van den Dolder, Beste Juliette, tijdens mijn promotie traject is onze 
samenwerking altijd prima verlopen! Naast onze maandagochtend 
gesprekken kon ik ook altijd tussendoor langskomen met praktische vragen of 
voor zomaar een praatje. Ook ons bezoek aan 'pretpark' NASA werd een 
onvergetelijke dag vol propaganda en een ritje op een (vervallen) jaren 60 
complex! Echter, er bleek minder plek op de afdeling te zijn voor het 
celgerelateerde onderzoek, waardoor je na 3 jaar je heil elders zocht. Maar, 
doordat je nog steeds in Nijmegen woont, ben je altijd te vinden voor een 
avondje gezelligheid en onderhoud je nog steeds een nauwe band met 
afdeling! 
 
Dr. van den Beucken, Beste Jeroen, als pas gepromoveerd persoon had je de 
lastige taak om mij in mijn laatste jaar te begeleiden. Ondanks dat er nog 
veel werk verricht moest worden, wist je toch strakke deadlines te stellen, die 
ik vervolgens niet altijd binnen de tijd wist te halen. Desondanks is alles toch 
binnen 4 jaar afgekomen, en dat was zeker niet gelukt zonder jouw bevlogen 
begeleiding! Verder waren de uitstapjes met de afdeling ook altijd erg 
gezellig, en wist je me keer op keer (luidruchtig) op te zadelen met niet-leuke 
vrouwen... Ook het feit dat je zo scherp kan blijven met zoveel chronisch 
slaapgebrek blijft een klein medisch wonder! 
 
Dr. Wolke, Beste Joop, dat je bij de meeste van mijn artikelen staat wil toch 
zeggen dat je een belangrijk aandeel hebt gehad in mijn promotie. Ook de 
kennis die je over de materiaalkunde hebt is zeer waardevol gebleken! 
Verder wist je altijd ongenuanceerde opmerkingen met veel humor te 
maken, waarbij je niemand spaarde. Ook was je de grote gangmaker van de 
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afdeling en in het bijzonder tijdens het jaarlijkse ‘lab-uitje’ in Lunteren, en dan 
moest het diner vaak nog beginnen! 
 
Drs. Bodde, beste Esther, doordat we als onderzoekers aan hetzelfde project 
verbonden waren, heb ik door jou veel ervaring opgedaan aan de 
praktische kant van ons project. Verder was het erg plezierig dat je jarenlang 
mijn 'buurvrouw' op de afdeling was. Ook de lawine van sneeuw tijdens je 
bruiloft zal ik altijd blijven herinneren. Desondanks werd het toch een 
memorabel feest! Veel succes met je promotie, zwangerschap en je 
opleiding! 
 
Ir. Habraken, Beste Wouter, doordat we als onderzoekers ook aan hetzelfde 
project verbonden waren, heb ik door jou veel ervaring opgedaan aan de 
chemische kant van ons project. Je kon urenlang praten over 'bolletjes' en 
hoe geweldig die waren. Door dit grote enthousiasme voor het onderzoek 
was je vaak ook niet weg te slaan bij mijn eigen onderzoek! Verder zijn je 
zang- en drinkkwaliteiten ook niet onopgemerkt gebleven. Veel succes met je 
promotie en je verdere carrière in Eindhoven! 
 
Prof. Dr. Mikos, Dear Tony, many thanks for the opportunity to stay at your 
department! It was a very experiencing period on a professional as well as on 
a personal level for me. Unfortunately, it is too time-consuming to travel all the 
way to the Netherlands, just to be present during my defence. Hopefully, we'll 
still see each other during international conferences. Also, many thanks to 
Quynh, Roy, Amit, Hansoo, Shiela, Simon and Zarana for making my stay in 
Houston a memorable one! 
 
Prof. Dr. Boerman, Beste Otto, heel erg bedankt voor de soepele 
samenwerking met je afdeling en de bereidheid tot het meedenken met het 
onderzoek. Hoewel het originele idee niet realiseerbaar was, werd er toch 
een alternatief gevonden, wat resulteerde in een publicatie. 
 
Naast de bovengenoemde personen wil ik ook nog andere personen 
bedanken die zeker niet onbelangrijk zijn geweest tijdens mijn 
promotietraject: 
De inmiddels ex-collega's van de afdeling Parodontologie & Biomaterialen: 
Adelina, Anja, Anne, Afsheen, Betsy, Corinne, Daniel, Dimitris, Edwin, Ellart, 
Fang, Frank, Harry, Hongbing, Jacky, Jan-Willem, Juliet, Jurgen, Kenichi, Kim, 
Lise, Manal, Martijn, Marijke, Meike, Natasja, Nelleke, Olga, Peter, Quinten, 
Remco, Sander, Vincent, Walter, Weibo, Xuechao, Yonggang en alle 
stagiaires. 
Hiervan wil ik nog een aantal mensen extra noemen. Ten eerste Adelina, voor 
het experiment wat we hebben uitgevoerd op de rattenschedels. Veel 
succes in Bulgarije en met de laatste loodjes van je proefschrift! Verder ook 
stagiair Wouter voor zijn hulp met mijn experimenten. Veel succes in 
Amsterdam met je promotie en je opleiding! Ten slotte kan ik niet voorbijgaan 
aan Anja, Jurgen, Martijn, Natasja en Vincent. Zonder jullie kennis van zaken 
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en hulp van de verwerking van de verschillende onderzoeken zou ik zeker nu 
nog bezig zijn, en zou alles niet zo soepel verlopen zijn. Een zegen voor elke 
onderzoeker! 
Verder was ik ook regelmatig ergens in het dierenlab te vinden, en zonder de 
kundige hulp van Alex, Brenda, Connie, Debby, Fred, Geert, Geertje, Gerry, 
Ilona, Jeroen en Wilma zou dat ongetwijfeld tot meer stress bij zowel de 
dieren als bij mezelf geleid hebben.  
 
Naast de professionele kant van het onderzoek doen heb ik me ook sociaal 
prima vermaakt op de afdeling. De koffiepauzes waren altijd een gezellige 
bijeenkomst van alle collega's waarbij diverse onderwerpen de revue 
passeerden. Niet zelden ontstond er dan ook een uitgelaten vrijdagmiddag 
sfeer, terwijl het dan pas vaak maandagochtend was. 
Ook moeten de onderzoekers in de 'gezelligste' promovendi-kamer genoemd 
worden. Hoewel die in de loop van de tijd van samenstelling en locatie 
wisselde was de (werk)sfeer altijd prima! Hoewel iedereen z'n zegje deed, 
blijven de (sterke) verhalen van Lise me toch het meest bijstaan. 
Naast de collega's van Biomaterialen was er ook geregeld contact met de 
'boefjes' van Orthopedie. Bewonderenswaardig was het 'beuls' werk wat 
geregeld werd uitgevoerd namens die afdeling, maar dat was aan René, 
Gerjon, Luc en Dennis wel goed besteed. Ook met Matrixbiochemie was er 
regelmatig contact, en met o.a. Paul en Martin was het prima toeven tijdens 
de gezamenlijke congressen en ook in downtown Londen.  
 
Verder kan ik niet voorbij gaan aan de vrienden en vriendinnen van 
(oorspronkelijk) Biomedische Wetenschappen, en dan met name de trouwe 
honden waarmee vanaf de studententijd tot aan het heden menig feestje is 
gevierd. Ook de doldwaze avonturen die op de skipistes en in de Yeti-bar 
werden beleefd waren onvergetelijk!  
Ook het team van Trekvogels 11 mag niet vergeten worden. Ondanks dat we 
in de kelder van het amateurvoetbal bivakkeren is de sfeer na (wederom) 
een verloren wedstrijd prima en hopelijk zal het team nog een hele tijd blijven 
bestaan! 
 
Tenslotte wil ik mijn familie bedanken voor al die jaren dat ze met hun 
onvoorwaardelijk steun achter me stonden. Ten eerste, jongere broer 
Christian met vriendin Stefanie. Chris, het was altijd gezellig om vanaf de 
jeugdjaren samen op te trekken en dezelfde hobby's te beoefenen. Veel 
succes de komende tijd om te slagen in de muziekbusiness! Stefanie, je wist 
met minimale informatie een maximale cover te maken. Fantastisch! Mijn 
ouders Peter en Els die mij op de wereld hebben gezet en ook nog eens een 
(goede) opvoeding hebben meegegeven. Ook staan jullie altijd klaar om me 
te helpen of bij te staan met goede raad! Ontzettend bedankt! 
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Dennis Link, geboren op 10 Juli 1977, groeide op in 
Zevenaar, waar hij de basisschool (de Tamboerijn) en de 
HAVO (Liemers College) doorliep. Vervolgens is in 2000 de 
ingenieurs titel behaald in de richting Medische 
Microbiologie van de Hogere Laboratorium Opleidingen 
te Nijmegen. Daarbij is stage gelopen en afgestudeerd bij 
het Regionaal Laboratorium voor de Volksgezondheid van Groningen en 
Drenthe te Groningen. Aansluitend heeft hij in 2003 de doctorandus titel 
behaald in de Biomedische Gezondheidswetenschappen van de Radboud 
Universiteit Nijmegen. Gedurende de opleiding is een wetenschappelijke 
stage gelopen op de Maag, Darm en Lever afdeling (Dr. Peters) van het 
Radboud Universiteit Nijmegen Medisch Centrum. Vervolgens is begonnen 
met het promotieonderzoek op de afdeling Parodontologie & Biomaterialen 
(Prof. Dr. Jansen) van het Radboud Universiteit Nijmegen Medisch Centrum in 
het kader van het Simon Stevin onderzoek 'New Bone'. De resultaten hiervan 
zijn beschreven in dit proefschrift. Gedurende het promotietraject is tevens 
onderzoek verricht aan de Bioengineering afdeling (Prof. Dr. Mikos) van de 
Rice University in Houston, Texas, USA. Verder heeft hij zijn onderzoek 
gepresenteerd tijdens verscheidende (inter)nationale congressen, inclusief 
het Tissue Engineering and Regenerative Medicine congres in Londen, 
waartoe een 'Travel Award' was toegekend. Vanaf 1 juni 2008 zal hij 
werkzaam zijn op de Biomaterials, Biodegradables and Biomimetics (3B's) 
afdeling (Prof. Dr. Reis) van de Minho University in Braga, Portugal.  
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